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ABSTRACT 
Membrane proteins, biological macromolecules that reside in cellular membranes, play 
critical roles in many biological process, including signaling, transport, and intercellular 
communication. The malfunction of membrane proteins has been linked to the initiation or 
progression of many diseases (e.g. autism, diabetes), so the study of their precise structure is of 
critical interest in the field of drug discovery and structure-based drug design. Structure-based 
drug development relies on the knowledge of atomic resolution 3D protein structures, the 
relationship between protein function and structure, and how these proteins interact with 
potential drug molecules. X-ray crystallography, presently the most common and robust method 
for solving structures, relies on the growth of high quality protein crystals. The structural pipeline 
reaches a bottleneck during X-ray crystallography because conditions for protein crystallization 
cannot be determined a priori –  extensive screening methods (i.e. trial and error) across a 
multi-parametric chemical space must be conducted to discover appropriate crystallization 
conditions using limited amounts of precious membrane protein sample. Analysis of eukaryotic 
genomes that 30% of all proteins are membrane proteins, however <2% of all known structures 
are membrane proteins. Given their significant role in disease and the slow pace of structure 
elucidation, new methods are needed to accelerate structure discovery for membrane proteins. 
The membrane protein crystallization toolbox contains many powerful, yet difficult-to-use 
tools. For example, nucleation and growth are typically coupled during crystallization 
experiments, which limits the degree of control over the quality and size of crystals grown in 
solution. Seeding techniques, where crystals grow from existing nuclei, provide a 
straightforward route to large, diffraction quality crystals. While simple in principle, seeding is 
difficult in practice because the experimental procedure requires the crystallographer to disrupt 
the equilibrium of the crystallization droplet, and oftentimes ruining the crystallization 
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experiment. This difficulty often leaves seeding as a ‘last resort’ technique. Another technique, 
in meso crystallization, maintains membrane proteins in a native-like membrane throughout the 
process of crystallization and has yielded very high quality crystals and structures of previously 
intractable membrane proteins. Unfortunately, the in meso method requires handling highly 
viscous lipid phases with specialized mixing and dispensing tools, and is thus limited to 
dedicated crystallographers and labs with robotic formulation systems. Regardless of the 
crystallization technique used, membrane protein crystals are incredibly fragile, so the final step 
of harvesting and mounting crystals prior to X-ray diffraction also hampers progress in structural 
studies. 
This dissertation details the development and application of a suite of microfluidic 
crystallization platforms designed to overcome technical difficulties in membrane protein 
crystallization. Specifically, these platforms enable crystallization condition screening for either 
seeding techniques or in meso techniques and subsequent in situ X-ray crystallography. 
This work improves upon the construction of X-ray transparent devices previously designed 
in the Kenis group and applies them to membrane protein crystallography. In Chapter 2, devices 
for separating nucleation and growth via crystal seeding were developed and applied to a model 
soluble protein and a target membrane protein. In Chapter 3, a novel microfluidic method for 
formulating in meso crystallization trials was developed and used to crystallize and solve the 
structure of a membrane protein. In Chapter 4, in meso crystallization devices for high-
throughput screening and optimization experiments were designed, and crystallization 
conditions for several membrane proteins of unknown structure were discovered. In the interest 
of directly studying protein-ligand or protein-drug interactions, a novel microfluidic method for 
growing and subsequently soaking crystals in meso was developed and applied to a model 
crystallization system in Chapter 5. 
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In summary, this work details the development of microfluidic platforms that automate 
membrane protein crystallization through a variety of techniques. These devices incorporate 
fine-control at the nanoliter scale and in situ analysis into high-throughput arrays to facilitate 
membrane protein structure determination. The development of platforms for in meso 
crystallization is particularly significant, as they represent the first X-ray transparent microfluidic 
platforms for in meso crystallization which also push the limits of scale and throughput when 
compared to state-of-the-art robotic in meso techniques. Further, when extended to studying 
protein-ligand and protein-drug systems via soaking, the in meso approach demonstrated here 
presents an attractive route to develop and study pharmaceuticals.  
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CHAPTER 1 
Introduction 
Proteins are biological macromolecules that carry out a large diversity of functions in living 
organisms, from enzymes that regulate biochemical activity to structural proteins that maintain 
the shape and integrity of cells.1 A pool of 20 unique amino acids and their specific arrangement 
in each protein confers on them this wide diversity of functions.2 Specific linear sequences of 
amino acids for each protein are encoded in genes on DNA, and the human genome, for 
example, contains genes for 20,000 unique proteins.3 Even though the exact amino acid 
sequences of proteins can be determined from the DNA, only the 3-dimensional structures of 
proteins at atomic resolution can provide the  key to understanding how and why proteins 
function . 
A more specific class of proteins, membrane proteins, reside in biological membranes where 
Figure 1.1: Progress in membrane protein structure determination. (a) All deposited structures as of April
2017. Membrane proteins represent <2% of all protein structures in the Protein Data Bank, while 30% of
all proteins are membrane proteins. (b) Accumulated number of protein structures in the Protein Data
Bank since 1970 (inset: membrane proteins). The pace of soluble protein structure solution exceeds that
of membrane proteins by 2 orders of magnitude. Figure created with data extracted from the Protein Data
Bank (www.rcsb.org) and Membrane Proteins of Known Structure (http://blanco.biomol.uci.edu/mpstruc/)
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they act as cellular gatekeepers and perform other pivotal functions in cellular energy production 
and regulation.1 While the discovery of protein structures has progressed and accelerated over 
the past 80 years, the number of published structures of membrane proteins lags behind those 
of water-soluble proteins – as of April 2017, over 120,000 protein structures have been solved 
and deposited in the Protein Data Bank, of which only 2,194 are membrane protein structures 
(Figure 1.1).4,5 While membrane proteins represent 20-30% of all proteins in prokaryotic or 
eukaryotic organisms,6 they only represent 1.8% of all atomic-resolution structures. While 
trending upwards from ~1.0% in 2010 thanks to dedicated structural biology initiatives, such as 
the National Institutes of Health (NIH) Protein Structure Initiative (PSI), significant bottlenecks in 
membrane protein expression, purification, and crystallization have hampered the rate of 
structure solution for membrane proteins. Herein lies a discussion of the high impact nature of 
membrane protein structures, the reasons for the lack of 3-D structures, and recent efforts to 
overcome bottlenecks. 
1.1 Structural biology and membrane proteins 
Protein structure is classified on four levels: (1) primary structure, the sequence of amino 
acids of the protein backbone, (2) secondary structure, the local folding and assembly into 
substructure elements such as α-helices and β-sheets, (3) tertiary structure, the full protein 
molecule fold in three-dimensional space, and (4) quaternary structure, the arrangement of 
protein molecules into a multi-subunit complex (Figure 1.2). Primary structure elucidation is 
easily and routinely accomplished by sequencing either the DNA that codes for the protein or 
the protein itself. Secondary structure elucidation is also straightforward to solve through 
predictive and spectroscopic methods (such as circular dichroism and infrared spectroscopy).7 
Large macromolecular assemblies can be observed with a variety of analytical techniques to 
determine quaternary structures. Tertiary structures, however, are typically the most difficult as 
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they must be solved at atomic resolution using techniques such as nuclear magnetic resonance 
(NMR),8 cryogenic electron microscopy (cryo-EM),9 or, most commonly, X-ray crystallography.10 
Without their unique 3-D folds, membrane proteins would not be able to serve diverse, 
specific and efficient biological roles.11 Located in cellular membranes, membrane proteins’ 
roles range from transporters of ions/molecules to signal receptors to respiratory enzymes. 
Consequentially, membrane protein misfolding or malfunction has been tied to the initiation and 
progression of many diseases, thereby making membrane proteins attractive drug targets 
(>60% of all drug targets).12 Conversely, drugs can be targeted to inhibit MPs in pathogenic 
bacteria to reduce the spread of certain diseases.13,14 Atomic resolution three-dimensional 
structures reveal key features of proteins, such as binding pockets for small molecules, docking 
locations on the protein surface for other molecules or proteins, and conformational changes. A 
thorough understanding of these structural features and interactions can accelerate structure-
based drug design to discover new cures for membrane protein linked diseases.15 
Photosystems and reaction centers are amongst the most well-studied membrane proteins, 
representing >150 structures in the Protein Data Bank. Photosynthetic proteins can transform 
Figure 1.2: Four levels of protein structure. At its simplest, a protein is comprised of a specific sequence
of amino acids which defines its primary structure. The secondary structure describes how these amino
acids locally interact with each other to form sub-structural elements, such as α-helices or β-sheets. The
tertiary structure describes how the entire amino acid chain folds in 3-D space. Quaternary structure
describes how the many protein molecules arrange into a multi-subunit complexes. Figure reproduced
from W.H. Freeman and Company (Lehninger Principles of Biochemistry, 4th Edition).  
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light energy into metabolic energy – when triggered with light, electron transfer propagates 
across a series of protein-bound co-factors, ultimately converting photons into chemical 
bonds.16 In 1984, photosynthetic reaction center was the first membrane protein to have its 3-D 
X-ray crystal structure solved,17 and this crystallization has been replicated many times. 
Because the crystallization system is robust and repeatable, photosystems and reaction centers 
are often used to test new membrane protein crystallization techniques18–22 and crystallographic 
methods.23–27 
Several noteworthy structural studies into membrane proteins have come from the G 
protein-coupled receptor (GPCR) family. GPCRs are a large family of receptors that recognize 
extracellular stimuli, transmit signals over ~30 Å across the cell membrane, and trigger a cellular 
response with the aid of G proteins.28 An estimated 30-40% of all drugs currently on the market 
target GPCRs.29 Until recently, biologists understood broadly the function of GPCRs but not 
specifically, structurally, how GPCRs convert a signaling stimulus into a cellular response. As a 
culmination of decades of research, 2011 marked a breakthrough for GPCR structures. The 
crystal structure of the β2 adrenergic receptor was captured while the protein was activated by a 
hormone agonist, providing the first high-resolution insight into the mechanism of signal 
transduction by a GPCR.30 When bound to an agonist, a transmembrane helix, TM5 extends by 
two rotations while TM6 shifts outward 14 Å, opening a docking site for a G protein which then 
then initiates a downstream function (Figure 1.3). The impact of this work earned Brian Kobilka 
and Robert Lefkowitz the 2012 Nobel Prize in Chemistry.31 Further, several other researchers 
have designed new agonists and antagonists based on the structure of the active site – for 
example, through structure-based drug design, several high efficacy and high potency agonists 
were designed based on the 3-D structure of the active β2 adrenergic receptor, including boric 
analogues of the native molecule32 and newly designed molecules.33  
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Heme-copper oxidases are another important superfamily of membrane proteins that couple 
oxygen reduction with transmembrane proton pumping during aerobic respiration.34–36 Recent 
advances have resulted in an X-ray crystal structure of a member from each of the four heme-
copper oxidase families, although the total number of structures, number of structures in an 
active state, and in some cases, structural resolution are low.37–41 For example, the structure of 
cytochrome bo3 oxidase (PDB: 1FFT) is only partially complete, although it provided enough 
evidence to propose the location of a quinone binding site.40 Notably, a follow-up report showed 
that a secondary, low affinity quinone binding site exists in this same membrane protein, 
although the structural quality was too poor to distinguish the second site in the partial 
structure.42 In other studies, structures of cytochrome c oxidase do not directly show the 
capacity for the currently proposed mechanisms – further studies and higher resolution 
structures are required to further elucidate mechanisms in these cases.43  
Figure 1.3: 3.2 Å resolution structure of the β2 adrenergic receptor from X-ray crystallography. (a,b) Side
and cytoplasmic views of the active receptor (green) compared to inactive structure (blue). Significant
structural changes are seen for the intracellular domains of TM5 and TM6. TM5 is extended by two
helical turns whereas TM6 is moved outward by 14 Å as measured at the α-carbons of Glu 268 (yellow
arrow) in the two structures. (c) The helix of a G-protein docks into a cavity formed on the intracellular
side of the receptor by the opening of TM5 and TM6. As the helix exits the receptor it forms a network of
polar interactions with TM5 and TM 3. Figures and caption adapted from Nature Publishing Group
(Rasmussen et al., Nature 477, 549 (2011).) 
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1.2 The challenge of obtaining membrane protein structures 
Several methods have been successfully employed to solve 3-D structures of membrane 
proteins, most notably NMR, cryo-EM, and X-ray crystallography. NMR is an attractive 
technique for obtaining structures under physiological conditions (i.e., conformational mobility, 
not constrained to a crystal lattice), but NMR studies of large, transmembrane proteins has been 
impaired by difficulties in preparing sufficient amounts of isotopically labeled proteins, limited 
thermal stability, and sample heterogeneity.44,45 While still in its infancy, structural biology with 
cryogenic electron microscopy (cryo-EM) has made many exciting advances over the past 
several years, from large to small membrane proteins.9 New detectors and computational 
methods have allowed the solution of “near atomic” resolution structures as low as 3.4 Å.46,47 
While at modest resolutions compared to X-ray structures (<2.0 Å), cryo-EM directly images 
single molecules and thus does not require crystals nor experimental phasing. While the field of 
cryo-EM seems to have many exciting years ahead, there are still many technical hurdles to 
overcome before cryo-EM becomes the preferred technique.48 The focus of the work herein 
utilizes the current state-of-the-art, X-ray crystallography, which has the widest applicability, 
best resolution, and is responsible for ~90% of membrane protein structures to date. X-ray 
crystallography measures the diffraction of X-rays from the lattice of a protein crystal (Figure 
1.4a). The theoretical limit in resolution is half the wavelength (λ) of light used for diffraction (for 
atomic resolution crystallography, λ = 1 Å). Full molecular structures are built by solving electron 
density maps from diffraction data collected at many orientations of a crystal or multiple crystals, 
and then fitting the sequence of amino acids to complete the overall 3-D fold of the protein 
(Figure 1.4b). 
In preparation for a crystallization experiment, proteins are expressed, purified and 
concentrated in a solution, and then mixed with precipitant (a mixture of salts, polymers, or 
small molecules that drive supersaturation). Water-soluble proteins are prepared in a buffered 
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solution, while membrane proteins are prepared in a buffered solution with detergent. 
Crystallization experiments are typically prepared in standard well plates in one of four methods: 
(1) vapor diffusion, (2) batch, or microbatch, (3) free interface diffusion, or (4) dialysis. In 
principle, in each method, the crystallization experiment enters supersaturation differently, either 
by slow gradient mixing (free interface diffusion, dialysis, vapor diffusion), or rapid mixing 
(microbatch). Under the ‘right’ conditions, protein crystals will grow out of solution. 
Unfortunately, there is no a priori method for determining what precipitants will drive crystal 
formation, so a wide variety of precipitants are tested via a sparse matrix screening approach.49 
Figure 1.4: Schematic of monochromatic X-ray crystallography and structure solution. (a) For X-ray data
collection from protein crystals, crystals are first looped onto a crystal mount and placed on an X-ray
goniometer in the path of an X-ray beam. The incident X-rays diffract into many specific directions and
the scattering pattern is measured using an X-ray detector. The crystal is then rotated into selected
orientations and many more diffraction images are recorded. (b) For each image, the angles and
intensities of the diffracted X-rays are identified and measured to determine the space group and lattice of
the crystal. For each image, every reflection is recorded, scaled, and reduced into a tabular format that
lists the Miller index (h,k,l) and intensity for each reflection. Next, computational software package is used
to determine the phase of the reflections, build electron density maps, build the 3-D protein structure, and
refine the structure. 
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After crystallization, the crystals are then harvested, flash frozen, and probed with X-rays to 
collect diffraction data. 
Protein sample preparation and crystallization gain an additional layer of complexity for 
membrane proteins due to their inherent amphiphilicity – as membrane proteins are natively 
situated in biological membranes, a portion of every membrane protein’s surface is hydrophobic, 
which renders them insoluble in aqueous solution. Amphiphilicity presents new challenges for 
expression, purification, and crystallization. The amount of membrane protein expressed is 
limited to the volume of two-dimensional membranes,50 yielding up to milligram quantities of 
precious membrane protein sample.51,52 As a result, the majority of structures come from 
membrane proteins that naturally express at high concentrations, or for membrane proteins that 
have been overexpressed in a homologous system.53 Before crystallization, membrane proteins 
must be removed from their native membrane through the addition of detergents and purified. 
Many proteins rapidly denature and aggregate when solubilized in detergents, although a 
variety of solubility enhancing tags and affinity tags have been developed to stabilize membrane 
proteins throughout the purification process.54  
Even when a membrane protein sample has been expressed and purified successfully, 
amphiphilicity still disturbs the crystallization process. Crystallization can be performed using the 
same methods as water-soluble protein crystallization, although the process is termed “in surfo” 
crystallization (in surfactant). Crystal formation requires protein molecules to form close crystal 
contacts, but these contacts are inhibited by the presence of stabilizing detergents on the 
hydrophobic transmembrane portions of the proteins. Consequently, crystals contacts form 
almost exclusively at the hydrophilic head and tail sections of the protein, resulting in low 
crystallization success rates and fragile, weakly diffracting Type II crystals.55 Comparatively, for 
water-soluble proteins, the entire surface is available for crystal contacts, and strongly diffracting 
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Type I crystals typically form (Figure 1.5). Despite the inherent reduced quality of crystals, 
many crystal structures have been solved from crystals grown in surfo. 
Due to the fragility of membrane protein crystals, the process of harvesting and mounting 
crystals are a significant experimental step prior to X-ray crystallography. Harvesting is 
performed with a pin mount that has crystal loop or a plastic mesh at the tip. The crystallization 
well is de-sealed and then crystals are manually picked out of the mother liquor with the mount 
and then flash frozen in liquid nitrogen to mitigate radiation damage.56 Crystals often sustain 
damage during the harvesting and freezing process which negatively impacts structural 
Figure 1.5: Schematic of two approaches for membrane protein (MP) crystallography. (Top) Detergent
solubilized MP is mixed directly with precipitant in the in surfo method. Vapor diffusion crystallization trials
are set up as either a ‘hanging drop’ or a ‘sitting drop’ and sealed in a closed well with precipitant as an
equilibration buffer. When crystals form in the drop, the detergent molecules at the MP surface typically
inhibit close crystal contacts, forming Type II crystals where the hydrophilic surfaces primarily make
crystal contacts. (Bottom) Detergent solubilized MP is mixed with a lipid, forming a cell membrane-like
bicontinuous lipid phase. Crystallization trials are typically set up as sitting drops or in a microbatch well.
When crystals form in meso, they crystallize stacked bilayers which facilitates formation of close crystal
contacts on both hydrophobic and hydrophilic surfaces, forming high quality Type I crystals. 
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data.57,58 Although not widely accessible, new techniques mitigate can mitigate some of these 
issues such as serial crystallography to mitigate radiation damage,59–61 automated harvesting 
approaches,62 and liquid jets63,64 or fixed targets65–67 to avoid crystal handling. 
1.3 Advanced techniques for membrane protein crystallization 
While in surfo crystallization methods have yielded many structures, several crystallization 
methods that enable crystallization success rates and grow higher quality crystals (larger or 
Type I crystals) have been successfully applied to membrane proteins. Notably, the application 
of two methods, microseeding and in meso crystallization, have both resulted in increased rates 
of crystallization and structure solution of previously intractable proteins.68,69 
Microseeding membrane protein crystallization. Microseeding of protein crystallization, the 
process of supplementing a crystallization experiment with previously grown crystal nuclei, 
decouples nucleation and growth. A fixed number of crystal nuclei are supplied to a 
supersaturated protein solution, resulting in the growth of a limited number of large crystals for 
X-ray diffraction experiments.  
The microseeding method has been extended to microseed matrix screening, where a 
homologous microseed (same protein) or heterologous microseed (e.g., other proteins, hairs, 
fibers) are introduced to high throughput sparse matrix screens for new crystallization 
conditions.70,71 With microseeds, crystals grow at both high and low levels of supersaturation 
which increases hit rates during sparse matrix screening. The best crystals are identified from 
the screen, and then the condition(s) are repeated and re-screened to obtain diffraction quality 
crystals as demonstrated in several reports.70,72–74 
The experimental methods for microseeding are difficult, and despite numerous successes 
with soluble proteins, just one membrane protein has been crystallized with microseeds.75 While 
simple in principle, the addition of microseeds is difficult in practice. Microseeds will often 
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dissolve in unmixed precipitant or protein solutions, thus the process of adding microseeds is 
delicate and time sensitive. Further, manual skill is required to de-seal crystallization wells to 
add nanoliters of microseed solution, a process which also inadvertently shifts the equilibrium of 
the crystallization experiment through incidental exposure to air. Specialized well plates and 
robotic technologies have been developed to increase the throughput of in surfo and 
microseeded crystallization by automating the formulation of vapor diffusion and microbatch 
droplets.68,76,77 A few robotic techniques have been designed specifically for microseeding, (e.g., 
robots from Douglas Instruments and TTP Labtech) but these robots cannot solve the time-
sensitive dissolution inherent to microseed addition. 
Crystallization of membrane proteins in meso. Bilayer methods for MP crystallization make 
use of extended bilayers composed of lipid, detergent, and proteins to stabilize and facilitate the 
process of crystallization.78 The most impactful of these methods, in meso crystallization, 
reconstitutes and stabilizes membrane proteins in a lipidic cubic phase, a bicontinuous lipid 
crystal mesophase that mimics a cell membrane throughout the crystallization process (Figure 
1.6).79 Although determining appropriate crystallization conditions still requires extensive sparse 
Figure 1.6: Cartoon representation of the events proposed to take place during crystallization in meso.
The process begins with the protein reconstituted into the curved bilayer of the ‘bicontinuous’ cubic phase
(tan). Added ‘precipitants’ shift the equilibrium away from stability. This leads to phase separation where
molecules (a) diffuse from the cubic phase into a sheet-like domain and (b) locally concentrate therein in
a process that progresses to nucleation and crystal growth…An expanded view of the various
components in the system is shown in (c). Figure reproduced from Li, Shah et al. (2013). Copyright 2013
American Chemical Society. 
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matrix screening, the primary advantages of crystallization in meso arise from the membrane 
protein remaining in a membrane throughout the crystallization process. Due to their 
confinement in a membrane, when MPs crystallize in lipidic mesophases they typically form 
closely packed and strongly diffracting crystals. The absence of detergent micelles enables both 
the hydrophilic and hydrophobic domains to make crystalline contacts in “Type I” crystals.55 
Since the discovery of in meso crystallization in the 1990s, many noteworthy crystal structures 
of membrane proteins, including the aforementioned GPCRs and heme-copper oxidases, were 
crystallized in lipidic mesophases.37,38,80,81 
The success of the in meso method relies on screening a large number of crystallization 
conditions,82 which requires repetitive use of specialized tools (e.g., coupled syringes, ratcheting 
syringes) to forcibly mix and dispense lipid and protein and overcome the high viscosity and 
non-Newtonian behavior of the mesophase (Figure 1.7).83 Automated screening approaches, 
robots, and novel crystallization protocols alleviate some of these problems,19,68,84,85 but 
harvesting protein crystals from mesophases is still performed manually. The typically small size 
Figure 1.7: Setting up an in meso crystallization trial involves (a) placing membrane-protein solution and
lipid into syringes connected by a coupler, passing the protein from one syringe to the other via the
coupler to mix the mesophase and reconstitute the protein, (b) transferring the mesophase into one
syringe, (c) replacing the empty syringe to a dispensing micro-syringe mounted in a repeat dispenser,
and (d) dispensing mesophase followed by precipitant solution into the wells of a glass sandwich plate.
Figure and caption reproduced from the International Union of Crystallography (Caffrey, Acta Cryst F 71,
3 (2015).). 
13 
of in meso MP crystals, 2-70 µm,86 which are embedded in the toothpaste-like mesophase 
makes harvesting them even more problematic than for in surfo crystallization. Both 
microseeding and in meso crystallization would benefit from easy-to-use technologies or 
devices to automation crystallization and facilitate analysis. 
1.4 Microfluidic devices for protein crystallization 
Microfluidic devices are tools to precisely control flow phenomena at sub-milliliter volumes, 
and have been applied in many research fields and commercial applications, from the analysis 
of single cells and molecules to next generation gene sequencing technologies. 
Polydimethylsiloxane (PDMS) is commonly used for developing and prototyping microfluidic 
devices because it is biocompatible, non-toxic, and optically transparent. Microchannels can be 
patterned in PDMS via soft lithography, and PDMS also has adhesive and elastomeric 
properties that enable facile bonding and the incorporation of integrated microvalves, enabling 
PDMS microfluidic devices to manipulate and mix just nanoliters of fluid with precision (Figure 
1.8). Microfluidic devices built out of thermoplastics (e.g., polymethylmethacrylate, cyclic olefin 
copolymer) have grown in popularity due to their compatibility with commercial manufacturing 
Figure 1.8: Two common types of valves used in microfluidic chips. (a) A normally-open valve – when
the control channel is pressurized with air, the fluid channel will flatten and stop the flow of a liquid. (b) A
normally-open valve – when vacuum is applied to the control channel, adhesive forces between PDMS
and the substrate are overcome and the valve stop raises to allow fluid flow. Panel a reproduced from
Multidisciplinary Digital Publishing Institute (Au et al., Micromachines 2, 179 (2011).), panel b reproduced
from Elsevier (Mohan et al., Sens. Actuators, B 160, 1216 (2011).). 
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processes, excellent optical properties, and impermeability.87 Microfluidic devices provide a 
facile route to scale down and scale out – through etching or lithography, channels and 
compartments at the micron scale hold just nanoliters of fluid and can be reproduced in highly 
parallel arrays. Due to the need for high-throughput screening at nanoliter-to-microliter scales, 
microfluidic devices are an attractive option for membrane protein crystallization.  
Compared to protein crystallization robots, microfluidic methods offer equivalent throughput 
(number of trials) and can use sample more efficiently (volume consumed per trial). Several 
efforts have been made to increase throughput and lower the usage of precious protein sample 
– in a notable report, Quake and co-workers developed a microfluidic crystallization device that 
Figure 1.9: Three microfluidic chips for protein crystallization. (a) Microfluidic array chip for protein
crystallization via free interface diffusion using as little as 10 nL of protein solution in arrays 144 wells.
Normally-open microfluidic valves separate protein and precipitant during filling, and is released for
mixing. (b) Microfluidic droplet mixer to formulate crystallization trials – droplets of protein and precipitant
are separated by water-permeable oil across which water will diffuse to induce crystallization. (c) X-ray
transparent microfluidic array chip for protein crystallization by free interface diffusion. Normally closed
valves separate protein and precipitant during filling. After crystallization, the entire X-ray transparent chip
is mounted in front of an X-ray beam for analysis. Panel a reproduced from Hansen et al., Proc. Natl.
Acad. Sci. USA 99, 16531 (2002), Copyright 2002 National Academy of Sciences. Panel b reproduced
from Wiley (Zheng et al., Angew. Chem. Int. Ed. 43, 2508 (2004).). Panel c reproduced from Elsevier
(Guha et al., Sensor. Actuat. B-Chem 174, 1 (2012).). 
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formulated 144 parallel free interface diffusion crystallization trials where each used just 10 nL 
of protein sample (Figure 1.9a).88 The automation and throughput were achieved by 480 active 
valves, and at its time, this device outperformed comparable methods in identifying 
crystallization hits while reducing sample consumption by two orders of magnitude. In another 
report, Ismagilov and co-workers developed a microfluidic system that formulated microbatch 
crystallization trials in 7.5 nL aqueous droplets at a rate of “several per second” under computer 
control (Figure 1.9b).89,90 In a third approach, Fraden and co-workers developed a device that 
formulated 1000 crystallization conditions by dialysis, storing 1 nL crystallization.91 These, 
among several other methods, demonstrate the translation of a variety of bench-top 
crystallization methods onto microfluidic chips.  
To avoid damaging crystals during the process of crystal harvesting (Section 1.2), many 
recent microfluidic devices are designed for X-ray transparency to allow in situ X-ray diffraction 
experiments. Crystals grown in microcapillaries have been used to successfully used for in situ 
crystallography.92 Thin thermomoplastic X-ray compatible well plates, such as the X-CHIP, have 
also been successfully used to solve crystal structures in situ.93 Sauter and co-workers 
performed a thorough study of chip materials and developed counter-diffusion chips for in situ 
X-ray analysis fabricated from PDMS, polymethylmethacrylate (PMMA), or cyclic olefin 
copolymer (COC) – the devices most compatible with X-ray crystallography were determined to 
be the ones made of COC and PMMA as determined by the quality of protein structure collected 
on each chip.94 Thick layers of PDMS were found to significantly scatters X-rays, increasing 
background noise when analyzing crystals in situ. A few other reports also focus on device 
development and advantages with COC and other impermeable, X-ray transparent materials.95–
97 Kenis and co-workers developed X-ray transparent microfluidic devices for crystallization by 
free interface diffusion with an overall thickness of <200 µm of COC and PDMS (Figure 1.9c).98 
A series of reports demonstrated that these devices are effective tools for serial crystallography, 
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de novo structure solution via anomalous diffraction,99 time-resolved crystallographic 
experiments with Laue pump-probe crystallography,100 and cryo-crystallography.101 
While numerous microfluidic technologies have automated nanoliter-scale fluid handling for 
protein crystallization in aqueous solutions, few methods have addressed the difficulties of multi-
step crystallization experiments such as microseeding or in meso crystallization. Microseeded 
crystallization trials are typically prepared manually or with a robot, with a few notable 
exceptions. Ismagilov and co-workers demonstrated a two-step seeding method for protein 
crystallization that modulated the concentrations of nanoliter sized droplets,102 and Kenis and 
co-workers demonstrated microfluidic microseed screening by free-interface diffusion to 
optimize crystallization for active pharmaceutical ingredients.103 Similarly, only two non-robotic 
methods have been reported for in meso crystallization: a nanoliter-scale droplet-based method 
for crystallization in pre-mixed or diffusively-mixed mesophases (Figure 1.10),19 and a high-
viscosity microfluidic mixer (Figure 1.11).84 These microfluidic approaches successfully 
Figure 1.10: Plug-based microfluidic system for in meso crystallization. (a) Schematic of the system.
Small mesophase plugs (~1 nL) were formed in a PDMS flow-focusing device using fluorinated carbon
(FC) as a carrier fluid and then they were merged downstream with the streams of protein and precipitant
to form LCP-containing aqueous plugs (~80 nL). The plugs of the crystallization trials were stored and
incubated at 23°C in Teflon tubing to allow crystals to grow. (b) A micrograph showing that LCP plugs
formed in the flow focusing device. (c) A micrograph showing that LCP plugs successfully merged with
precipitant and protein solutions. (d) A micrograph showing that there was no cross contamination
between plugs. (e) Crystallization of reaction center from Blastochloris viridis. Figure and caption adapted
from Springer (Li et al., Microfluid Nanofluid 8, 789 (2010).). 
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crystallized membrane proteins in meso, although their application has not been expanded to 
high-throughput screening and in situ crystallography.  
In summary, significant efforts have produced a wide diversity of microfluidic devices for 
protein crystallization, and a few have reached commercialization. To eliminate the steps of 
crystal handling and mounting, X-ray transparency is a highly desirable feature for these 
devices. Despite the advantages of microfluidic devices for manually intensive techniques such 
as microseeding or in meso membrane protein crystallization, there has been far less 
development in user friendly and high-throughput microfluidics. Further, due to the fragile nature 
of membrane protein crystals, in situ analysis on X-ray transparent devices is a highly attractive 
route to 3D membrane protein structures. The melding of scalability, fluidic control, and X-ray 
transparency for advanced crystallization techniques presents a great potential for new devices 
that can advance the frontier of structural biology of membrane proteins. 
Figure 1.11: Microfluidic lipidic mixer for in meso crystallization. (a) Optical micrograph of a microfluidic
chip capable of mixing lipids (L) and aqueous protein (Pr) solutions by pneumatic actuation of the
isolation valves (black) between the chambers and the injection valves (purple and blue) on top of the
three large chambers (2-Pr, L). Crystallization occurs in a separate chamber where the mesophase is
combined with a precipitant solution that is introduced from a separate circular chamber at the top. (b-c)
Optical micrographs of a homogeneous mesophase being moved from the mixing chambers into the
crystallization chamber by actuation of the mixing chamber valves. Scale bar: 500 µm. (d) Optical
micrograph of the resulting bacteriorhodopsin crystals grown on-chip via the in meso method. Figure and
caption adapted from the American Chemical Society (Perry et al., Cryst. Growth Des. 9, 2566 (2009).). 
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1.5 Summary and key challenges 
The identification of crystallization conditions is a significant bottleneck in the membrane 
protein structural biology pipeline because conditions cannot be determined a priori. High-
throughput screening is a necessity, and microfluidic devices have facilitated screening for 
numerous soluble proteins. Advanced crystallization techniques, such as microseeding or in 
meso methods, can offer a higher probability for success of membrane protein crystallization, 
but there is a noteworthy lack of accessible enabling technology for crystallization trial 
formulation, condition screening, and in situ crystallography. The ideal microfluidic tools to 
accelerate structural biology with these advanced crystallization techniques would: (1) automate 
the multi-step mixing process for aqueous or lipidic cubic phase crystallization trials, (2) enable 
in situ crystallography via X-ray transparency, and (3) be simple and easy-to-use for the 
average crystallographer. 
Microseeded crystallization offers a reliable route to large, diffraction quality crystals by 
decoupling nucleation and growth, although the process of adding microseeds to an equilibrium 
crystallization experiment is a challenge. Chapter 2 focuses on the development and 
application of X-ray transparent microfluidic devices that control the difficult process of adding 
microseeds to crystallization experiments for both soluble proteins and membrane proteins in 
surfo. 
In meso crystallization requires the preparation of highly viscous mesophases, and then 
subsequent addition of precipitant to trigger crystallization. Previous approaches have faced 
significant challenges in formulation of mesophases (<10 nL) in a high-throughput manner for 
crystallization and in situ diffraction. Chapter 3 details the development and application of in 
meso crystallization devices to simplify and automate the process of mesophase formulation 
and solve a membrane protein structure from on-chip data. Chapter 4 details the extension of 
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this work into high-throughput arrays and applies the devices to the crystallization of several 
membrane proteins of unknown structure. 
After crystal growth, soaking small molecules into crystals can provide structural evidence 
for binding or docking sites, or even mechanistically important structural changes. Crystal 
soaking, however, has been shown to be prohibitively difficult when in meso crystals are grown 
traditionally in glass-sandwich plates and beyond the capabilities of automated in meso 
crystallization robots.104 Chapter 5 discusses the development and application of a 
straightforward method for soaking inhibitor molecules into membrane protein crystals grown 
with in meso crystallization devices. 
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CHAPTER 2 
X-ray Transparent Microfluidic Platforms for 
Microseeding Membrane Protein Crystallization* 
2.1 Introduction
Protein crystal formation can be conceptualized in terms of composition-composition phase 
diagrams in which concentrations of protein and precipitant map the solubility and aggregation 
properties of protein solutions.1 Such a crystallization phase diagram (Figure 2.1) is constructed 
by mixing a protein and a precipitant at specific, increasing concentrations until the cloud point 
is observed to identify the precipitation boundary, and the dissolution of crystals to identify the 
solubility boundary. Between these two extremes are two distinct zones of supersaturation: the 
Figure 2.1: Simplified protein crystallization phase diagram. The phases, in increasing orders of 
supersaturation are: soluble, metastable, labile, and precipitation. (a) The formulation of two 
microbatch droplets, points C and F, is illustrated. Composition C is formulated by mixing a droplet of 
composition A with a droplet of composition B (1:1 mixing ratio), while composition F is formulated by 
mixing a droplet of composition D with a droplet of composition E (1:1 mixing ratio). (b) A typical 
trajectory during a microbatch crystallization experiment. Droplet F will form new nuclei and grow 
crystals, while droplet C will not form new nuclei and remain at a metastable concentration, growing 
no crystals. (c) The same crystallization experiments supplemented with microseeds – pre-exisitng 
nuclei grow into large, ordered crystals. 
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metastable region and the labile region. Crystallization trials formulated at concentrations in the 
labile region result in spontaneous nucleation and successful crystallization, while those 
formulated in the metastable region result in no new nucleation (Figure 2.1b). Conceptually, the 
formation of new nuclei is unfavorable in the metastable region, but favorable in the labile 
region. -Oftentimes, a crystallization trial formulated in the labile region results in uncontrolled 
nucleation producing hundreds of tiny crystals that are unfit for single crystal X-ray diffraction. 
These problems can be overcome through careful inspection of the phase diagram and through 
techniques such as microseeding to separate the processes of nucleation and growth.2 
During initial crystallization experiments, any resulting microcrystals, irregular crystals, or 
other semi-crystalline phases, while not useful for X-ray diffraction, can be collected and 
crushed to form a solution of submicroscopic crystal nuclei.2,3 Microseeding, the process of 
introducing such nuclei into a crystallization mixture, has been demonstrated to be a powerful 
tool for growing large, diffraction-ready protein crystals.4–9  The process of microseeding 
decouples two steps in crystal formation – nucleation and growth – by supplying a finite number 
of nuclei into a metastable protein-precipitant mixture. In principle, when microseeds are 
introduced into a metastable mixture, no self-nucleation events occur in the droplets and only 
the supplied nuclei will grow into crystals (Figure 2.1c).  
The application of microseeds also extends to routine screening experiments in a method 
known as microseed matrix screening. When screening for crystallization of a new protein target 
with an unknown crystallization phase diagram, the addition of microseeds can promote ordered 
crystal growth and enhance screening success rates.10–13 Microcrystals from an initial screen 
are crushed to form microseeds, and then used during re-screening of the same or a different 
set of conditions.  The best conditions from the resulting screen are harvested and the process 
is iterated to produce diffraction-quality crystals. With the aid of microseeds, the number of 
protein crystallization conditions discovered increases because both metastable and labile 
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compositions will produce crystals, effectively broadening the chemical space for successful 
crystallization screening. Microseed matrix screening has been used successfully in cases 
where the best conditions for crystal growth without seeding lead to precipitation,7 to accelerate 
crystal growth of proteins complexed with hydrolysable substrates where the absence of 
seeding resulted in a hydrolyzed substrate,14 to crystallize antibody-antigen complexes,4 and 
many more cases.15–18  
Many efforts to simplify and automate microseeding have been successfully implemented for 
various proteins.11,12,19,20 Microseeding robots pre-mix the protein, precipitant and microseed 
solution during crystallization set up.11  Femtosecond laser ablation has been used to eject 
crystal fragments that serve as seed in the same crystallization drop.21  Acoustic matrix 
microseeding utilizes acoustic waves to deliver nanoliter volumes of seed suspension into 
protein drops.22  Despite the promise of improved crystallization success with microseeding, it 
remains an under-utilized tool and is often chosen as the last resort when all other attempts to 
grow high quality crystals have failed.  In all methods, the procedure for making microseed stock 
solutions is the easy part, while the introduction of microseeds to the crystallization droplet 
requires skill and experience when performed manually. Alternatively, microseeding robots can 
perform routine microseed matrix screening, but robots with this capability are not commonly 
available in structural biology labs. Further, no method provides a non-intrusive method for 
introducing microseeds after a droplet reaches metastable equilibrium. 
In this work, we report two microfluidic methods to simplify the process of microseeding and 
the application of methods to photoactive yellow protein (PYP, soluble protein) and cytochrome 
bo3 oxidase (cyt bo3, membrane protein). Microfluidic array chips are easy to use for 
researchers of any skill level and enable non-invasive incorporation of microseeds during an in-
progress crystallization experiment by free interface diffusion across normally closed 
microvalves. In the first method, metastable mixtures of PYP and cyt bo3 were formulated off-
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chip, introduced into a microfluidic chip, and mixed with several different microseed dilutions to 
observe the impact of microseeds and find the best conditions for crystallization. For both 
proteins, microseeds at greater dilutions resulted in larger, less clustered crystals.  A separate 
chip was developed to perform microseed matrix screening – in this approach, protein and 
precipitant were mixed on-chip at various compositions, and then, after incubation, mixed with 
microseed solutions. Importantly, this chip gives full control over the timing of seed introduction, 
preventing incidental seed dissolution during mixing. Results with cyt bo3 showed localized 
areas of the composition-composition crystallization phase diagram where crystals of different 
diffraction quality and morphology could be grown. While the crystals obtained in this work did 
not result in an atomic resolution crystal structure, the method presented here demonstrates the 
use of these microfluidic chips as enabling technologies to reliably screen, troubleshoot, and 
analyze the crystallization of finicky membrane proteins with microseeds. The activation barrier 
for using this technology is low, as the only peripherals necessary for operation are pipettes to 
place solutions at the inlets, a small vacuum pump to actuate valves for filling and mixing, and a 
stereo-zoom microscope to observe the chips for crystal growth. 
2.2 Materials and methods 
Protein preparation. Photoactive yellow protein from Halorhodospira halophila was cloned and 
expressed in Escherichia coli (strain BN9626) and purified as published previously.23 Briefly, 
polyhistidine-tagged apoPYP heterologously over-expressed in E. coli was reconstituted in vitro 
with the anhydrous derivative of the chromophore p-coumaric acid and the polyhistidine-tag was 
cleaved by incubating it with enterokinase. 
Cytochrome bo3 oxidase (cyt bo3) from Eschierichia coli (strain C43(DE3)) was purified as 
published previously.24 Briefly, polyhistidine-tagged cyt bo3  was overexpressed by IPTG 
induction in E. coli and solubilized in dodecylmaltoside. Prior to crystallization, the sample was 
29 
treated with 1 mM potassium ferricyanide to fully oxidize the protein and exchanged into 20 mM 
Tris-HCl, pH 8 with 0.7% beta-octylglucoside. 
Fabrication of photoresist-on-silicon masters for replica molding. Photoresist-on-silicon 
masters were created by photolithography with SU8-2050 photoresist25 (Microchem) for patterns 
with 50-100 µm-tall vertical features. All photoresist-on-silicon masters were treated with 
(tridecafluoro-1,1,2,2-tetrahydrooctyl) trichlorosilane (Gelest, Inc.) in a vacuum chamber for 4 h 
for easy release of soft lithographic replicas.26  
Fabrication of thin PDMS/COC microfluidic devices. The PDMS layers were fabricated using 
standard replica molding procedures26,27 by spin-coating the photoresist-on-silicon masters with 
PDMS to obtain a PDMS film height ~10 µm thicker than the corresponding photoresist feature 
height. For the fluid layer PDMS with the monomer:cross-linker ratio of 15:1 was cured at 90 °C 
for 7-9 min. For the control layer PDMS with the monomer:cross-linker ratio of 5:1 was cured at 
90 °C for 3 min. 
The chips were assembled as follows: (i) a flat COC sheet was irreversibly bonded to the 
PDMS control layer, and (ii) the resulting COC-PDMS assembly was irreversibly bonded to the 
PDMS fluid layer. Permanent COC-PDMS bonding in step (i) was achieved by activating the 
surfaces using atmospheric plasma treatment28 in a plasma cleaner (Harrick, Model PDC-001) 
for 1 min at 500–700 mTorr. Permanent PDMS-PDMS bonding in step (ii) was created via the 
standard multilayer soft lithography approach27 by placing layers of PDMS with different 
monomer:cross-linker ratios in conformal contact and heating them at 70°C for 2 h. Inlet holes 
for the control and the fluid layer were drilled in the COC-PDMS-PDMS assembly using a 300 or 
750 µm drill bit (McMaster-Carr). The assembly was then placed on an unpatterned COC 
substrate and a reversible bond between the PDMS fluid layer and the COC substrate formed 
spontaneously.  
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Crystallization in well plates. Vapor diffusion in hanging drops was set up as published 
previously.29,30 Un-seeded crystallization in well plates yielded clusters of crystals after 7-10 
days of incubation for PYP, and microcrystalline showers for cyt bo3. These crystals, while 
unsuitable for X-ray analysis because of difficulties in isolating individual crystals from the 
clusters or microcrystalline showers, were used to create microseed solutions. Crystals from 2-3 
crystallization wells each for PYP and cyt bo3 were harvested from hanging drops and 
transferred into 500 µL of a concentrated precipitant solution (PYP: 3M ammonium sulfate, cyt 
bo3: 13% PEG 1500), and then transferred to a tissue grinder (Kontes Duall model K885460-
0021, Thermo Fisher Scientific Inc) where they were crushed gently to make the stock 
microseed solution. Various concentrations of the microseed solutions were prepared by serially 
diluting the stock solution in concentrated precipitant solutions at ratios of 1:1, 1:2, 1:4, 1:10, 
1:20, and 1:50. Repeating the same crystallization experiments at reduced concentrations in 
well plates with microseeds successfully yielded crystallization after 2 days. Microseed stocks 
and dilutions were either used immediately or flash frozen in liquid nitrogen and stored at -80°C 
until use. 
Computational fluid dynamic simulations of mixing time. Diffusive mixing of protein in 
microfluidic compartments was simulated using a 2D finite element solver, COMSOL 
Multiphysics (COMSOL Ltd.). The lateral dimensions of six different sets of protein and 
precipitant compartments in this model are identical to those in the actual chip. A ‘No Flux’ 
boundary condition was applied to external walls and non-mixing interfaces. When mixing, the 
valves areas raise and leave an open liquid-liquid interface for free interface diffusion. The 
model simulated 60 minutes of mixing at 1 minute intervals. The mesh was “finer”, with a total of 
1319 elements. The initial concentrations of cyt bo3 oxidase were 10 mg/mL – 50 mg/mL, and 
the diffusion coefficient was 4 x 10-7 cm2/s.31 The initial concentration of PEG 1500 was 0.07 
mM, and the diffusion coefficient was 3 x 10-6 cm2/s.32 The solutions were assumed to dilute and 
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that the diffusion coefficients were independent of concentration. For each half-well, the average 
concentration was calculated using a surface integral and scaled to the actual height of the 
microfluidic well (50 µm). 
Synchrotron X-ray data collection and analysis. X-ray diffraction data were collected at APS 
(Advanced Photon Source) synchrotron, Argonne National Laboratory at beamline 23-ID-B 
GM/CA (General Medical Sciences and Cancer Institutes Structural Biology Facility). Data were 
collected from all cyt bo3 crystals that produced diffraction in 0.2–0.4° steps with 0.2–0.4 s 
exposures and a sample-to-detector distance between 500–600 mm with a Pilatus 6M detector. 
All data were collected at room temperature. During diffraction experiments, each crystal in 
each well was numbered and recorded to match diffraction data to its corresponding protein-
precipitant composition. 
Image analysis of cytochrome bo3 oxidase crystals. Images of cyt bo3 crystals were 
captured using an upright stereo microscope (Leica MDG33) equipped with a macro lens and a 
digital camera (Leica DFC295). Images were analyzed manually using ImageJ. The length and 
width of up to 30 crystals in each well were recorded and correlated to the protein-precipitant 
condition used for crystal growth. 
2.3 Microseeded crystallization of photoactive yellow protein and 
cytochrome bo3 oxidase  
Multilayered microfluidic chips designed for high X-ray transmission were fabricated to 
facilitate the addition of microseeds at variable concentrations to crystallization experiments. In 
a 24-well array, sets of integrated microvalves controlled the metering and mixing of metastable 
crystallization mixtures and microseed solutions. Devices were comprised layers of PDMS, a 
flexible polymer that enables the functionality of valves, sandwiched between thin layers of 
cyclic olefin copolymer, a rigid polymer that acts as an impermeable barrier to air and water 
(Figure 2.2a). At a total thickness of ~200 µm, these chips have been demonstrated to be 
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effective all-in-one tools for crystal growth and in situ serial X-ray data collection at room 
Figure 2.2: A simple approach for microseeding on a microfluidic chip. (a) Exploded view of a single 
crystallization well comprised of three thin layers: a PDMS fluid layer containing compartments and 
valves for liquid solutions, a COC layer containing vacuum lines for valve actuation and windows, and 
a COC substrate to seal the chip for experiments. This work substitutes a COC-PDMS control layer for 
the shown COC control layer. (b) Schematic of the design of a 24-well array chip used for 
microseeding. Fluid layer is shown in black, and the various valve lines, V1, V2 and V3, are colored 
based on their function (see legend). The window structures (yellow) are present to decrease the total 
material present in the path of the X-ray beam. For microseeding experiments, a gradient of 
microseed dilutions were loaded (inlets 2-7) and mixed with a pre-mixed protein-precipitant solution 
(inlet 1). (c,d) Results from screening several microseed dilutions – at greater seed dilutions (lower 
seed concentration), PYP crystals (c) grew into fewer, larger crystals and cyt bo3 crystals (d) grew into 
fewer, thicker crystals. Figure 2.2a and 2.2b adapted with permission from Elsevier (S. Guha, S.L. 
Perry, A.S. Pawate, and P.J.A. Kenis, Sens. Actuators, B 174, 1, 2012)  
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temperature (>75% X-ray transmittance at λ = 1Å).  
The operation of a similar device has been described in previous work.33 Briefly, 3 µL of a 
pre-formulated protein-precipitant mixture was placed onto inlet 1 and introduced to the protein-
precipitant half-wells by dead-end filling (Figure 2.2b), a vacuum-actuated process that 
displaces air in each compartment with the protein-precipitant mixture as air permeates through 
a thin PDMS layer separating the fluid layer from the control layer. 1 µL of a microseed solution 
was placed onto each microseed inlet (ports 2-7), and they were also introduced to microseed 
half-wells by dead-end filling. The normally-closed valve separating the two half-wells was then 
opened for 5 minutes to allow mixing of microseeds and the protein-precipitant mixture by free 
interface diffusion. 
As validation, the effect of microseeds on crystallization was tested for two proteins: (1) 
photoactive yellow protein, a protein that grows into well-ordered crystals only in the presence of 
microseeds, and (2) cytochrome bo3 oxidase, a fragile membrane protein with a known 
crystallization condition that has previously produced some crystals and an incomplete, low 
resolution structure. Microseeding experiments on-chip were performed by first preparing 
metastable 1:1 solutions of protein and precipitant in an Eppendorf tube (20 mg/mL PYP with 
2.6 M ammonium sulfate, 15 mg/mL cyt bo3 with 10% w/v PEG 1500, 100 mM HEPES pH 7.0, 
100 mM NaCl, 100 mM MgCl2, and 5% ethanol) and allowing the solution to equilibrate for 1 
hour on ice. Each mixture was then introduced to a microfluidic chip. Serial dilutions of 
microseed solution were introduced through inlets 2 through 7 to fill the half-wells adjacent to 
the protein-precipitant mixtures (Figure 2.2b). The metastable protein-precipitant mixture and 
microseed wells mixed by diffusion for 5 minutes by opening the microvalve that separated the 
wells. Control experiments without microseeds resulted in no crystal growth, verifying that the 
mixtures were metastable rather than labile.   
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A range of microseed dilutions were tested, from 1:1 (high concentration) to 1:50 (low 
concentration. With microseeds, crystals first appeared after 1 day and reached full size after 4 
days (PYP) or 7 days (cyt bo3). For both proteins, high concentrations of microseed resulted in 
many small or needle-like crystals. As microseed concentration decreased, fewer, larger 
crystals grew (Figure 2.2c,d). These observations agree with expected trends for crystal growth 
with microseeds – at lower microseed concentrations, fewer crystals grow to larger sizes, while 
at higher microseed concentrations, more crystals grow to smaller sizes. A 1:20 microseed 
dilution yielded large, isolated crystals for PYP, while a 1:50 ratio yielded the thick, individual 
crystals of cyt bo3. The disparity in these optimal dilution ratios has two origins: first, depending 
on the protein and its solubility, some number of microseeds may dissolve during the mixing of 
the metastable mixture with microseeds. Second, an imprecise number of crystals were used to 
generate microseed stock solutions, so the true microseed concentration varies from seed stock 
to seed stock. Regardless, once an ideal microseed dilution was determined, large crystals 
could be reliably grown by repeating crystallization with the same seed stock.  
X-ray diffraction data were collected for PYP and cyt bo3 crystals on-chip. The entire 
microfluidic chip was mounted on a magnetic cap mount with a set screw and placed onto the 
goniometer. Due to the construction from X-ray transparent polymers and low thickness, 
crystals were targeted and analyzed at room temperature using the on-axis microscope 
available at the beamline. PYP crystals diffracted to a maximum resolution of 1.19 Å, and a 
structure was solved at 1.32 Å. The diffraction data set had high quality diffraction spots and 
good signal-to-noise, characteristic of good data collected from this on-chip approach and 
comparable to other crystallographic studies of PYP. The crystals from the membrane protein, 
cyt bo3, however, diffracted poorly, with sparse spots up to ~12 Å. While this microseeding 
method aided the growth of large cyt bo3 crystals, the diffraction reveals that even with 
microseeds, the quality of the crystals was poor. This crystallization condition requires further 
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optimization – a search across the cyt bo3 / PEG 1500 composition-composition phase diagram 
may lead to higher quality crystals.  
2.4 Microseed-assisted re-screening of cytochrome bo3 oxidase 
Typically, microseed matrix screening is performed by: (1) pre-mixing microseeds into the 
protein solution of precipitant solution, which results in partial or complete dissolution of 
microseeds in undersaturated solutions (Figure 2.1), or (2) pre-mixing microseeds into the 
protein-precipitant mixture immediately after mixing, which faces similar potential problems of 
microseed dissolution, or (3) adding microseeds at some time after equilibration, which requires 
that the crystallographer opens the crystallization well leading to the unwanted effect of 
upsetting the equilibrium between the crystallization drop and the vapor phase around it. The 
automation and precision of microfluidic chips provide an alternative route to incorporate 
Figure 2.3: (a) Schematic of the design of a 24-well three-component array chip used for 
microseeding, with fluid lines in black, and the various valve lines, V1, V2, and V3, colored based on 
their function (see legend). (b) Exploded view of a single well, showing device construction with a total 
material thickness of ~200 µm. (c) Top view of the aligned fluid layer and control layer, showing 
relative positions of protein, precipitant, and microseed compartments and the two separate mixing 
valves. 
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microseeds into a metastable mixture without significantly disturbing the crystallization droplet. 
To evaluate the sensitivity of diffraction resolution to position on a composition-composition 
phase diagram for cyt bo3, a 24-well microseed matrix screening array was employed using a 
new microfluidic chip with two separate free-interface diffusion mixing steps: (1) protein and 
precipitant mixing, waiting for equilibration, and then (2) protein, precipitant and microseed 
mixing (Figure 2.3). Compared to the earlier microfluidic approach where a single point on the 
composition-composition phase diagram was generated by pre-equilibrating protein and 
precipitant off-chip, this chip generates an array of protein-to precipitant ratios on-chip for 
optimizing a precipitant or a screening random matrix of precipitants with microseeds. The keys 
to this design are the arrangement of microfluidic wells to facilitate filling and mixing, and the 
separation of mixing valves to introduce the microseed at any time after protein-precipitant 
mixing (Figure 2.3c).  
 Three sets of normally closed microvalves control filling and mixing. First, protein, 
precipitant, and microseed are simultaneously introduced into separate microfluidic 
compartments by dead-end filling initiated by actuation of valve set 1 (Figure 2.4b-i). Next, 
protein and precipitant mix by free-interface diffusion by opening valve 3 for 30 minutes (Figure 
2.4b-ii). Then the valve is closed and the protein and precipitant wells incubate for 1 hour to 
reach a metastable composition. Valve 2 is then opened for 5 minutes to introduce microseeds 
to the metastable protein-precipitant mixtures (Figure 2.4b-iii). This final mixing step for 
microseeds introduction is short to introduce just a few seeds to the metastable mixture and to 
prevent large composition shifts in the metastable droplets. The chips are then sealed and 
incubated at 4°C or 20°C, and monitored daily for crystallization. 
The amount of time for crystallization and the final concentrations of protein and precipitant 
were determined through computational fluid dynamics simulations. Diffusion coefficient for cyt 
bo3 in water was estimated to be similar to other large proteins (hemoglobin: 64.5 kDa, 6.9 x 10-
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7 cm2/s; catalase: 247 kDa, 4.1 x 10-7 cm2/s). A reported value for the diffusion coefficient of the 
Figure 2.4: Sequence for mixing and filling steps for microseeding in three-component array chip.  (a) 
Schematic of array chip showing inset of a single crystallization well – three sets of mixing valves are 
indicated on the inset, (1), (2), and (3). (b) Schematics (1 – before filling or mixing;  2 – after filling or 
mixing) and optical micrographs (right) of step. Arrows indicate free interface diffusion interfaces (b-i) 
Protein, precipitant, and microseed are placed on their respective inlets, and actuation of valve line 1 
initiates dead-end filling. (b-ii) Valve line 2 is actuated for 30 minutes to mix protein and precipitant. 
(b-iii) After 1 hour of incubation, metastable protein-precipitant mixtures have formed (light and dark 
purple). Valve line 2 is then actuated for 5 minutes to introduce microseeds to each metastable 
mixture. 
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precipitant, polyethylene glycol, in water was modeled (3.2 x 10-6 cm2/s). The geometry of 
microfluidic wells at each protein-to-precipitant ratio were constructed and free-interface 
diffusion was simulated for 60 minutes at 1 minute intervals (Figure 2.5a). Diffusion of protein 
and precipitant were modeled, although precipitant rapidly mixes to completion on time-scales 
for protein mixing, so this discussion will focus on protein concentrations. Time-concentration 
plots were constructed by a surface integral of concentration in the protein well and precipitant 
well separately (Figure 2.5b). Diffusive mixing of protein nears completion after 60 minutes. 
Mixing for 30 minutes (as indicated, Figure 2.5b) results in an intermediate where two different 
metastable compositions are generated in each ‘half-well’ (Figure 2.5c). As a sample point, 
after 30 minutes with a 40 mg/mL protein solution, mixing results in 12 different protein 
Figure 2.5: Computational fluid dynamics simulations using COMSOL to determine mixing times and 
final concentrations. (a) Snapshots of protein concentrations over a 60-minute free interface diffusion 
simulation. (b) Integral concentrations at each time point in the protein compartment (left) and the 
precipitant compartment (right) for each of 6 different compartment sizes. On-chip experiments ran for 
30 minutes, indicated by the red dashed line. (c) Concentration surfaces of three intermediate-sized 
crystallization wells after 30 minutes. 
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concentrations ranging from 13 mg/mL to 32 mg/mL. At this timescale, the precipitant mixes to 
completion in all wells. This method was used to quantify concentrations for further discussions 
of composition-composition phase diagrams.  
Cytochrome bo3 oxidase microseeding experiments were set up as discussed with a range 
of stock protein concentrations between 10 mg/mL and 50 mg/mL. Stock precipitant solutions 
contained 9-12% w/v PEG 1500, while the other components (NaCl, MgCl2, HEPES, ethanol) 
were held constant. The optimal microseed dilution from the previous study, 1:50, was also 
found to produce large, individual crystals in these chips and is used for all experiments 
discussed herein. Crystallization results were recorded after 7 days and pictures were taken of 
each crystallization well for image processing. X-ray diffraction experiments were conducted 
within 14 days of setting up crystallization trials. As a control experiment, a separate chip was 
set-up with 30 mg/mL cyt bo3 and 9-12% w/v PEG 1500 and no microseeds.  Crystals did not 
grow in any wells for this experiment, validating that either undersaturated or metastable 
compositions (no native nucleation) were formulated at these intermediate concentrations. 
Diffraction data and crystal aspect ratios were mapped on protein composition / 
precipitant composition phase diagram to evaluate the influence of microseed screening on 
crystal habit and diffraction resolution (Figure 2.6). A solid line to indicate protein solubility was 
drawn on phase diagrams by inspection based on experiments that did not grow crystals with 
microseeds. The phase diagram with diffraction data shows that diffraction quality segregates 
into a few distinct regions – at the high and low ends of protein-to-precipitant ratio, crystals 
diffracted strongly up moderate resolutions (9 Å), while at intermediate protein-to-precipitant 
ratios, crystals diffracted to much poorer resolutions (>12 Å) (Figure 2.6a,c). This measure 
indicates that the best regions for crystallization lie close to either axis at high concentrations of 
either protein or precipitant. Further, a phase diagram that maps crystal aspect ratios (long axis 
to short axis) shows differences in crystal habit that depend on crystallization composition. At 
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low-to-moderate protein concentrations and high precipitant concentrations, crystals formed in 
shorter, rectangular or cubic shapes. At moderate-to-high protein concentrations and low-to-
moderate precipitant concentrations, crystals formed in long, needle-like shapes (Figure 
2.6b,d). Interestingly, the needle-like crystals typically diffracted poorly, while the 
Figure 2.6: Microseed screening results for cytochrome bo3 oxidase. (a) Composition-composition 
phase diagram showing different regions of average X-ray diffraction resolution for crystals, as 
indicated by the size and color of each point. (b) Composition-composition diagram showing crystal 
aspect ratios -  needle-like crystals (aspect ratio > 5) grew more often at low precipitant 
concentrations, while thicker crystals grew (aspect ratio < 5) grew at more at high precipitant 
concentrations. (c) Average diffraction resolution at each protein-precipitant ratio – the best diffracting 
crystals (<9 Å) typically grew at high and low extremes, while poorly diffracting crystals (>12 Å) grew 
at intermediate compositions. (d) Diffraction trends plotted for – longer, needle-like crystals typically 
diffracted the most poorly. 
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rectangular/cubic crystals diffracted better. This process shows that the quality and morphology 
of crystallization can be controlled by microseed screening over the crystallization phase 
diagram. The higher quality crystals, while not of sufficient for structure solution, were sufficient 
for data indexing due to strong, albeit low resolution diffraction. Further, the regions of the ‘best’ 
crystals indicate compositions that future experiments should sample. This set of experiments 
with cytochrome bo3 oxidase reached the upper limits of protein concentration, so further 
crystallization experiments with this protein should search for new precipitants through random 
microseed matrix screening for the best chance of uncovering crystals that diffract to atomic 
resolution.  
2.5 Conclusions 
In summary, microseed-assisted crystallization of soluble and membrane proteins was 
demonstrated on two different microfluidic array chips. These approaches exploit the 
phenomena of nucleation and growth to prevent the growth of small, uncontrolled showers of 
crystals in favour of large crystals that can be used for X-ray diffraction experiments. First, 24-
well array chips with wells comprised of two compartments, one for a metastable protein-
precipitant mixture and the other for a microseed solution, were used to crystallize photoactive 
yellow protein (PYP) and cytochrome bo3 oxidase. Optimal seed dilutions were determined to 
grow the best crystals for known crystallization conditions. Microseeded PYP crystals diffracted 
very strongly to 1.19 Å, however cytochrome bo3 oxidase crystals diffracted poorly to ~12 Å 
despite their large size, indicating that despite microseeds, this composition of protein and 
precipitant does not support the growth of high-quality crystals.  
To screen for better crystal growth with microseeds, a new 24-well microfluidic array chip 
was developed with three separate compartments for protein, precipitant, and microseed. In two 
separate mixing steps, the new array first mixes a gradient of metastable protein-precipitant 
solutions, and then introduces microseed through a separate mixing step. The results from 
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these experiments showed that diffraction quality and aspect ratio (shape) depend on the 
composition of protein and precipitant, where some composition ranges favor small aspect ratio 
crystals with decent diffraction, and other composition ranges favor large aspect ratio crystals 
with poor diffraction. While even the best crystals from this screen were not suitable for solving 
the structure of cytochrome bo3 oxidase, this microfluidic method demonstrates that the 
oftentimes unpredictable crystallization behaviour of fragile membrane proteins can be 
controlled through a systematic search of a composition-composition phase diagram with 
microseeds. 
Looking forward, this technique can be used widely as an effective, non-invasive method of 
incorporating microseeds into crystallization droplets. A membrane protein like cytochrome bo3 
oxidase could be re-screened with a new set of precipitants with routine addition of microseeds 
– such a method has been demonstrated to increase crystallization hit rates. Further, for 
processes that require tight control over crystal quality and morphology, these microfluidic chips 
are useful analytical tools for generating gradients of conditions to determine phase diagrams. 
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CHAPTER 3 
X-ray Transparent Microfluidic Device for 
Mesophase-Based Crystallization*
3.1 Introduction 
While the dual hydrophobic-hydrophilic characteristic of membrane proteins imparts them 
with unique characteristics and functions, it also hinders membrane protein expression, 
purification, and crystallization. To handle membrane proteins in solution, detergents are 
introduced and to stabilize the hydrophobic core of membrane proteins. Detergents have 
unfortunately have negative ramifications for crystallization experiments - in aqueous solutions, 
the presence of detergents has been shown to inhibit the formation of close crystal contacts, 
generally resulting in crystals with mediocre diffraction quality.1 While techniques like in surfo 
crystallization and more advanced microseeding methods have attempted to overcome the 
problem through exhaustive screening and manipulation of the crystallization phase diagram, 
many membrane proteins remain intractable to crystallization in aqueous solution. 
Lipidic mesophases are bicontinuous lipid bilayers that spontaneously assemble when lipids 
of the monoacylglycerol family are mixed with aqueous solutions, forming either a lamellar, 
cubic, or hexagonal bilayer phase.2 In 1996, the first report on the use of lipidic cubic phases 
(LCP) for membrane protein crystallization was published.3 Over the next two decades, the LCP 
method, also known as the in meso method, emerged as a powerful alternative to membrane 
protein crystallization from detergent solutions.4 By first reincorporating membrane proteins into 
a cell membrane-mimetic bilayer, amphiphilic membrane proteins stabilize and concentrate in 
the membrane prior to the addition of precipitants to trigger crystallization. When the addition of 
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salts and precipitants swell or contract the cubic phase, membrane protein molecules can 
nucleate and grow to form a high-quality crystals.5,6 The robustness and effectiveness of the 
LCP method has been highlighted through the structural determination of several previously 
intractable membrane proteins, most notably the β2-adrenergic receptor-Gs protein complex.7    
Prior to an LCP crystallization experiment, mesophases are prepared by >50 cycles of 
mixing in coupled-syringes. Subsequent manipulation of the mesophase is difficult due to the 
high viscosity and stickiness of lipidic mesophases, which requires specialized tools such as 
ratcheted syringe dispensers or dispensing robots.8,9 Even with these tools, fragile crystals must 
be manually harvested from mesophases prior to X-ray analysis, a challenging task even for 
many experienced crystalllographers. Next, harvested crystals are flash-frozen in liquid nitrogen 
and maintained under cryogenic conditions to prevent radiation damage during data collection.9 
The typically small size, 2-70 µm,10 of membrane protein crystals makes this procedure highly 
challenging. The damage caused to the delicate crystals during these steps may severely 
compromise the quality of resulting diffraction data. 
Numerous examples of microfluidic technologies that automate fluid metering and drastically 
reduce sample consumption have been demonstrated for various applications, including protein 
crystallization from aqueous solutions.11–14 While a number of X-ray transparent microfluidic 
devices that eliminate manual crystal handling, none have been applied to X-ray analysis of 
crystals in LCP.15–23 Further, only 2 prior approaches have attempted to simplify and automate 
the formulation of and crystallization in LCPs,24,25 and neither overcomes the hurdle of crystal 
damage sustained through harvesting. Both platforms rely on complex operation strategies and 
have numerous limitations due to the difficulties of manipulating viscoelastic materials in 
microscale compartments. 
Herein, we present the first microfluidic device that combines LCP crystallization capabilities 
with X-ray transparency in a simple design that requires only a small vacuum pump to introduce 
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reagents.26 To overcome the viscoelasticity of the lipidic mesophases, this approach mixes 
membrane protein and lipid passively by free-interface diffusion,27,28 after which crystallization is 
triggered by the introduction of precipitants. As validation, we crystallized the photosynthetic 
reaction center from Rhodobacter sphaeroides and solved its structure to a resolution 2.5 Å 
using data collected on-chip at room temperature. We also compared our room temperature 
structure (298 K) to cryogenic structures (100 K) and made observations about the effect of 
temperature on diffraction data quality and structural flexibility. 
3.2 Materials and methods 
Protein preparation. Rhodobacter sphaeroides photosynthetic reaction center (RC) was 
expressed and purified as described previously.29 The RC solution at an initial concentration of 
6 mg/mL in 10mM Tris pH 7.8, 280 mM NaCl, 0.05% LDAO (N,N-dimethyldodecylamine N-
oxide) was concentrated in a Microcon centrifugal filter device (Millipore Corp.) with a 10,000 Da 
cut-off by spinning in a microcentrifuge at 10,000 g in a cold room maintained at 4°C. The 
volume of the concentrate was measured after every 5-min spin and the centrifugation was 
stopped when the final volume reached ¼ of the initial volume, yielding a solution with a 
calculated final concentration of 24 mg/mL. The filtrate was used to dilute this solution to obtain 
samples with RC concentration of 10–24 mg/mL. The solutions were either used immediately for 
crystallization trials or separated into 2–3 µL aliquots and kept in the freezer at -12°C before 
using.  
Precipitant preparation. Precipitants for protein crystallization trials were formulated by first 
preparing an aqueous solution of 1 M HEPES (Sigma Aldrich) and 1.15 M (NH4)2SO4 (Fisher) 
and adjusting the pH to 7.5. Jeffamine M-600 (Hampton Research) was then mixed with the 
aqueous solution to obtain mixtures containing 11, 12, 13, and 14% w/v of Jeffamine. 
Lipids. Monoolein (Sigma Aldrich, 99%) was used as received. 5% v/w and 10% v/w solutions 
of ß-octylglucoside (OG, Anatrace, Anagrade) were prepared by dilution from a 20% v/w OG 
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Figure 3.1: Photomasks for producing silicon-on-photoresist masters with SU-8 negative photoresist for 
12-well mesophase-based microfluidic devices. (A) Fluid layer, for routing protein and precipitant 
solutions, (B) the control layer, for vacuum actuation, (C) the substrate, for the lipid chambers, and (D) an 
auxiliary chip for filling lipid into the substrate. 
solution in 25 mM NaH2PO4, pH 5.5. NaH2PO4 was obtained from EMD Chemicals.   
Equipment. Filling and mixing of microfluidic devices were monitored using an upright 
microscope (Leica MDG33) equipped with a macro lens and a digital camera (Leica DFC295). 
Valves were actuated using a vacuum pump (GAST, Model DOA-P704-AA) or house vacuum.  
Fabrication of photoresist-on-silicon masters for replica molding. Photoresist-on-silicon 
masters were created with SU8-2050 photoresist (Microchem) for patterns with 40-65 µm-tall 
vertical features and with SU8-25 photoresist (Microchem) for patterns with 25 µm-tall vertical 
features.30 All photoresist-on-silicon masters were treated with (tridecafluoro-1,1,2,2-
tetrahydrooctyl) trichlorosilane (Gelest, Inc.) in a vacuum chamber for 4 h for easy release of 
soft lithographic replicas.31  
Fabrication of patterned cyclic olefin co-polymer (COC) substrates. Patterned COC 
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substrates  were fabricated by hot embossing using the procedure developed by Guha et al.23 
Briefly, polydimethylsiloxane (RTV-615 PDMS, Momentive Performance Materials) with 10:1 
monomer:crosslinker ratio was used to fabricate a thick (several mm) inverse master of the 
photoresist-on-silicon master. PDMS was held at 75 °C for 2 h for curing. An epoxy master 
(Conapoxy FR 1080) for use in hot-embossing was then molded from the PDMS master. The 
epoxy components (83:100 hardener:epoxy, by mass) were mixed using a planetary centrifugal 
mixer (Thinky USA) for 15 min at 2000 rpm with rotation and then de-foamed for 12 min at 2200 
rpm. The epoxy mixture was poured into the inverse PDMS master and cured on a level hot 
plate at 120 °C for 4 h. To prevent evolution of gas bubbles from the PDMS master during 
epoxy curing, the mold was degassed either for ~10 min under vacuum at room temperature or 
heated on the hot-plate at 120°C for 20 min prior to filling it with epoxy. The PDMS master could 
be re-used several times for epoxy molding. Hot embossing was done in a laminating press 
(Carver, Model 3851) under the load of 150–200 kg. For high-fidelity pattern transfer, a stack of 
(i) 7–10 mm PDMS slab, (ii) an epoxy mold, (iii) a COC sheet, and (iv) a 7.5 × 5 cm microscope 
glass slide was placed between the platens of the press. The temperature of the assembly was 
brought to 177°C and then down to below 121°C before removing the patterned layer. Holding 
at 177°C for an extended period was not required for accurate pattern transfer. Non-patterned 
COC sheets were flattened between glass slides at 177°C and a load of 150–200 kg in the 
laminating press prior to use to obtain sheets with smooth surface. 
Fabrication of thin PDMS/COC devices. Hybrid microfluidic devices consisted of a flat COC 
top layer, a thin PDMS control layer, a thin PDMS fluid layer, and a patterned COC bottom layer 
(Figure 3.1A, B, C). The fabrication method for these thin PDMS/COC microfluidic devices is 
discussed in detail in Chapter 2.2. For details in the usage of this device, see Section 3.3.1. 
Fabrication of auxiliary PDMS devices for lipid filling. Thick PDMS devices were fabricated 
for lipid filling into the patterned COC substrate. The devices consisted of a several mm-thick 
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PDMS layer with patterned control and fluid channels (Figure 3.1D) and of a 20 µm-thick 
unpatterned PDMS film. The thick PDMS layers were prepared by pouring a mixture with the 
monomer:cross-linker ratio of 5:1 on the photoresist-on-silicon master followed by curing at 
90°C for 5-10 min. The thin unpatterned layers were spin-coated onto an unpatterned silane-
treated silicon wafer using PDMS with the monomer:cross-linker ratio of 15:1 and cured at 90°C 
for 7-9 m. 
The devices were assembled as follows: (i) inlet ports were punched in the thick layers using 
a 20 AWG needle with a thin wire plunger, and (ii) the thick layers were irreversibly bonded to 
the thin layers by placing the two layers in conformal contact and heating at 70 °C for 2 hours 
following the standard soft lithography approach.32  
For filling the COC substrates with lipid the parts of thin membranes to be located over the 
lipid chambers were pulled out carefully with sharp tweezers. The part of the membrane 
enclosing the channels remained intact in this step because of the different lateral dimensions of 
the channels and the circular endpoints. The assembly was then placed a patterned COC 
substrate, and a reversible bond between the PDMS fluid layer and the COC substrate formed 
spontaneously. For details in the usage of this device, see Section 3.3.2. 
Crystallization of photosynthetic reaction center in well plates. Protein crystallization in 96-
well flat bottom microplates (Corning CrystalEX 3785) replicated the protocol and crystallization 
conditions reported by Wallace et al.,27 although dry monoolein was used instead of preparing 
the lipid mesophase with water. Monoolein was dispensed into the well plate (0.2 µL/well) using 
a ratchet dispenser (Hampton Research), covered with Crystal Clear Sealing Film (Hampton 
Research) and stored at -12°C for up to 3 weeks before crystallization experiments. Prior to use, 
the plates were brought to room temperature before removing the tape.  
For crystallization, 0.4 µL of the RC protein solution was added on top of dry monoolein in 
the wells, sealed, and incubated for 4–12  h at 20°C. Afterward, 2 µL of the precipitant solution 
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was added to the crystallization well and 5-10 µL of the same solution was added to the 
reservoir well. The plates were sealed and incubated at 20°C. Protein crystals of 5-60 µm in 
size formed in 24-48 h.  
On-chip crystallization of photosynthetic reaction center. Protein crystallization on-chip was 
carried out with the same materials and incubation times as used in the crystallization in well 
plates. The volumes of protein and precipitant used for crystallization on-chip were determined 
by the volume of the chambers of the chip (~60 nL for protein, 244 nL for precipitant). After the 
chips were filled, the inlets were carefully sealed with Crystal Clear tape to minimize 
dehydration. 
Protein crystals of 5 – 80 µm in size appeared within 48 h and continued growing through 
96 h. Crystal X-ray diffraction data were collected within 10 d.  
Synchrotron X-ray diffraction data collection. Following our previously developed on-chip 
data collection strategy,23,33 small wedges of data from multiple crystals were collected and 
merged into a single data set for building electron density maps. The ease of growing and 
analyzing multiple (tens to hundreds) isomorphous crystals in a single chip enables data 
collection under ambient conditions with minimal radiation damage. In contrast, traditional 
crystallographic protocols rely on the harvesting and mounting of a single crystal at a time, 
followed by the analysis of that crystal under cryogenic conditions to minimize radiation 
damage.34 The challenges associated with this one-at-a-time manual protocol render analysis of 
multiple LCP-grown crystals at ambient conditions impractical. 
Protein crystal X-ray diffraction data were collected at macromolecular crystallography 
beamline 21-ID-F of the Life Sciences Collaborative Access Team (LS-CAT), Advanced Photon 
Source, Argonne National Lab. The beamline is equipped with a microdiffractometer (MAATEL 
MD2) consisting of a goniometer, XYZ micropositioner and an on-axis video microscope. The 
beamline operates at a fixed wavelength (λ = 0.979 Å, 12.7 keV) and has a MarMosaic 225 
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detector (Rayonix). A beam-defining aperture of 50 µm in diameter was used to control the 
footprint of the beam.  
Data were collected using an unattenuated X-ray beam with a 2–4 s exposure and 1° 
rotation per image with a sample-to-detector distance of 200 mm. Crystal quality typically 
declined after 5 exposures. Optimal exposure settings were determined by testing exposures on 
additional crystals grown on-chip. Data were collected from 56 crystals grown in 12 different 
wells in 3 different chips for these experiments, and 23 crystals were selected to form an optimal 
dataset for the final structure. Crystals had moderate variability in size (60–100 µm in the 
longest dimension) and produced diffraction data with comparable quality, resolution and lattice 
parameters. 
A second dataset was collected off-chip from protein crystals grown in well plates, where 
crystals were harvested using microloops (Hampton Research), flash-frozen in liquid nitrogen 
without the addition of cryoprotectant,10 and kept under a cryostream during data collection.  
Analysis of X-ray diffraction data. Analysis of X-ray diffraction data collected at the 
synchrotron was performed using HKL2000 software for indexing, refinement, integration, and 
scaling (HKL Research Inc.).35  The resolution range of the data was established based on the 
point at which the highest resolution shell’s I/σ fell below 3 provided that Rsym was also less than 
0.7. Subsequent processing of crystallography datasets was done using the Phenix suite of 
programs.36 Molecular replacement37 was done in Phaser using PDB structure 2UWW as a 
model.38 Model refinement was performed using phenix.refine.  Electron density maps were 
displayed using Coot and PyMOL.39,40 Ligands bound to the structure were identified in the 
electron density and built into the final model. The loosely bound ubiquinone (QB) was not fully 
resolved in the structure, but it is modeled into its approximate position. 
3.3 Microfluidic device for crystallization in lipidic mesophases 
In the 12-well chip presented here (Figure 3.2A), each well relies on diffusion to mix 60 nL 
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of protein solution and 10.5 nL dry lipid for mesophase formulation, and 244 nL of precipitant 
solution to induce crystallization. The protein solution is layered on top of the lipid, significantly 
reducing the diffusional path and, consequently, the mixing time compared to the traditional 
side-by-side placement of microfluidic compartments.33,41–43 The chip screens two crystallization 
conditions in parallel and can be easily modified for more extensive screening.  
For X-ray transparency, the chip is assembled (as discussed in Section 3.2.2) from four 
polymeric layers with a combined thickness of only ~200 µm. Fluid flow and precise dispensing 
in the chip relies on channels, compartments and normally-closed valves patterned in two layers 
of elastomeric polydimethylsiloxane (PDMS) (Figure 3.2B, C). Top and bottom cyclic olefin co-
polymer (COC) layers (Figure 3.2C) impart rigidity as well as a barrier against water 
evaporation. Fluid flow and compartment filling in the PDMS fluid layer is achieved by applying 
negative pressure (vacuum) to microfluidic control lines in the PDMS control layer (Figure 3.2B, 
C).  
After fabrication, the chip is comprised of two separable pieces: (1) a three-layer assembly 
Figure 3.2: (A) A photograph of the 2 x 6-well array chip. Lilac dotted lines (1-5) indicate the different
control lines connected to control valves. (B) Magnified top view schematic of a single crystallization well
comprised of three patterned layers and a top COC layer: first layer (PDMS, lilac) contains control lines
and valves, second (PDMS, black) and third (COC, red outlines) layers contain sample compartments.
(C) Cross section of a crystallization well showing the layered assembly of the chip. 
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Figure 3.3: Device architecture and the sequence of operations in the lipid filling step. (A) Superimposed
patterns in the hot-embossed COC substrate (red) and in the auxiliary thick PDMS layer (green) of the 2 x
6-well microfluidic platform for LCP crystallization. (B) A magnified top view of a single well and (C) the
cross-section of the PDMS assembly aligned with the patterned COC layer. Features in the top PDMS
layer correspond to lines 1 and 2 as indicated in (A-C). (D) The sequence of steps in the lipid-filling
protocol. (D1) The part of the thin PDMS membrane corresponding to the circular end of line 1 in (A) is
removed with sharp tweezers. (D2) The PDMS assembly is placed on the COC substrate. Application of
negative pressure (vacuum) to line 2 results in air withdrawal from line 1 due to air permeability of PDMS
and draws molten lipid into the chamber through line 1. (D3) The lipid fills the entire chamber in 5-10 min.
After filling, the lipid is frozen and remains solid at room temperature. (D4) The auxiliary PDMS layer is
removed, the crystallization layer is aligned over the filled substrate and the chip is ready for
crystallization. 
(TLA, with a COC impermeable cover layer, the PDMS control layer, and PDMS fluid layer), and 
(2) the COC bottom substrate containing solid lipid. For crystallization experiments, the TLA is 
reversibly sealed to the COC substrate, exploiting the adhesive properties of PDMS. All COC 
films used in this work had a thickness of 50 µm (2 mil) and were of grade 6013. The chamber 
height in PDMS fluid layers was 40–65 µm, and the chamber height in PDMS control layers and 
embossed COC sheets was 25 µm.  
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Deposition of lipid into COC substrates. Prior to combining the TLA and COC substrate, an 
auxiliary PDMS device was used to deposit monoolein into the respective 25 µm-deep 
chambers of the COC substrate (Figure 3.3). Monoolein was melted (Tmelt = 37 °C), filled into 
each 25 µm-deep chamber, and then frozen by applying dry ice for 10 minutes. The auxiliary 
device was then removed. Handling lipid in the molten state enabled accurate metering of 
nanoliter (microgram) quantities. Because monoolein is solid at room temperature, the lipid-filled 
substrates could be easily manipulated in subsequent steps once monoolein was solidified.  
The auxiliary PDMS device contained two sets of channels patterned in the thick PDMS 
layers and sealed by bonding a thin PDMS layer to the thick layer (Figure 3.3C). One set of 
channels was used as a fluidic line and consisted of branched channels that terminated above 
the patterned chambers in the COC substrate (Figure 3.3D). The thin PDMS membranes were 
carefully removed at the ends of the channels to form a continuous fluidic path between the inlet 
port and the chambers patterned in COC (Figure 3.3D). The other set of channels, used as a 
control line, passed over the patterned chambers and was connected to the vacuum source.  
To fill monoolein, negative pressure (vacuum) was applied to the control line. Although the 
line was separated from the chambers with the thin PDMS membrane, pressure gradient 
between the chambers and the inlet port of the fluidic line formed due to the air permeability of 
PDMS, and monoolein was drawn into the chambers through the fluidic line (Figure 3.3-D2), 
eventually filling all chambers in the substrate (Figure 3.3-D3). Device architecture ensured that 
monoolein only remained in the COC chambers once the PDMS layer was removed (Figure 
3.3-D4) as the fluidic lines themselves were sealed from the contact with the substrate. 
Formulation of mesophase-based crystallization trials on-chip. After the lipid is filled into 
the COC substrate, the TLA is aligned over the bottom COC substrate (Figure 3.4A).The on-
chip crystallization protocol presented here mimics a LCP crystallization variant that was 
performed in well plates.27  Through a single inlet (Figure 3.2A), the protein solution is 
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introduced into the 12 crystallization wells and is brought into direct contact with the lipid 
(Figure 3.4B, G). In the crystallization compartment, only the area above the lipid, the 
mesophase chamber (Figure 3.2B), is filled. Filling of the rest of the crystallization well with 
protein solution is prevented by a capillary valve geometry44 (obtained by appropriate choice of 
channel dimensions and wall angles) located between the mesophase and the precipitant 
chambers (Figure 3.2B). Incubation of the protein solution with the lipid results in spontaneous 
formation of the protein-enriched mesophase27,28 (Figure 3.4). After a 4–12 h incubation, 
precipitant solution is introduced. The mesophase stays in place due to its high viscosity45 
(Figure 3.4D). Under favorable conditions, incubation of the precipitant with the protein-
Figure 3.4: (A-E) Sequence of steps in the LCP protein crystallization protocol on-chip; (F-H)
corresponding optical micrographs of the mesophase chamber. (A,F) The hybrid COC/PDMS/PDMS
assembly is placed on the COC substrate pre-filled with lipid. COC, yellow; PDMS, blue; lipid, gray.
(B,G) Protein solution is combined with the lipid through the corresponding fluid line by applying negative
pressure (vacuum) to control lines 1 and 2. (C) Protein-enriched mesophase forms spontaneously upon
incubation and (D) precipitant is introduced by applying negative pressure to control lines 3, 4, and 5.
Line 2 in (B) and lines 3 and 5 in (D) serve to increase the rate of air withdrawal from respective sample
chambers. (E,H) Protein crystals form in the mesophase after incubation. (I) Representative example of
RC crystals grown on-chip. 
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enriched mesophase results in crystal formation in the mesophase (Figure 3.4E, I).  
Like the strategy presented for lipid filling, this protocol also fills solutions into their 
respective chambers through actuation of negative pressure (vacuum) to control lines (Figure 
3.4). The formation of a pressure gradient in the fluid layer due to the air permeability of PDMS 
displaces air pockets and enables complete filling of each device compartment. 
3.4 On-chip crystallization and X-ray analysis of R. sphaeroides 
reaction center 
Note: Although RC crystallization conditions likely produce a “sponge phase” rather than a 
true LCP,46 the term “LCP crystallization of proteins” is commonly used regardless of the exact 
mesophase type formed under specific crystallization conditions, and is utilized throughout this 
discussion of RC crystallization 
Figure 3.5: (A) Optical micrograph of an X-ray transparent chip for LCP crystallization mounted on
beamline 21-ID-F at LS-CAT, ANL. (B) Section of a crystallization well with crystals as seen in the on-
axis video microscope during X-ray data collection. The red circle represents the location and the
footprint of the 50 μm X-ray beam. (C) Example of X-ray diffraction data from an RC crystal on-chip at
RT. (D) RMSD visualization along the periplasmic side of our RT structure and a cryogenic structure
(PDB ID: 2GNU). Residues in grey were not included in calculation. Image was generated using the
ColorByRMSD script in PyMOL.40 
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Room temperature X-ray diffraction data collection for reaction center. We validated our 
approach by crystallizing photosynthetic reaction center (RC), a membrane protein from  
Rhodobacter sphaeroides, using previously reported crystallization conditions27 to obtain 
crystals of up to 80 µm in size (Figure 3.4I). We collected X-ray diffraction data at room 
temperature (RT) from crystals in the chips (“on-chip”) and solved the crystal structure of RC to 
a resolution of 2.5 Å (Table 1). The chips were mounted directly, without modification, on the 
goniometer at beamline 21-ID-F at the Advanced Photon Source (APS), Argonne National Lab 
(ANL) (Figure 3.5A). Diffraction data from the crystals were easily resolved (Figure 3.5C) 
despite background scattering from chip materials (Figure 3.6).  The excellent optical properties 
of the chips facilitated crystal targeting during data collection (Figure 3.5A, B). In contrast, 
crystals grown in parallel using the classical LCP method in microplates were difficult to locate 
in standard loop mounts because of the opacity of the mesophase (Figure 3.7).10,47  
Figure 3.6: A. A scattering pattern obtained with an empty chip shows two diffuse scattering rings. 
B. Scattering profile for 50- and 100-µm-thick COC films and for a hybrid PDMS/COC microfluidic 
chip (cumulative PDMS thickness 20 µm, cumulative COC thickness 75 µm); q is the scattering 
vector related to d-spacing as q = 2/d. COC films show background scattering centered at the value 
of q of 1.2 Å-1 (d-spacing of 5.2 Å). Standalone thin PDMS films were not probed due to their lack of 
rigidity. However, comparison of background scattering from the COC films with that from the chip 
indicates that the scattering from PDMS is centered at the value of q of 0.835 Å-1, corresponding to 
d-spacing of 7.5 Å. 
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Comparison of on-chip room temperature and cryo- RC structures. The structure 
determined from on-chip data (Table 3.1) agreed well with previously published structures of 
LCP-crystallized RC obtained using the traditional crystallization and data collection approach 
(PDB ID: 2GNU48, PDB ID: 1OGV49). The merged dataset for our structure was complete (Table 
3.1), indicating that on-chip crystals were oriented randomly. Our RC structure was 
isomorphous with the structures reported previously48,49 and had comparable structural 
statistics, refinement parameters, and final structural resolution. Values for Rsym and I/ for the 
on-chip structure were typical of good diffraction data.  
We also observed several important differences between cryogenic structures of RC48,49 and 
our RT structure. First, the lattice parameters of our RC structure were up to 1.8% larger than 
those reported previously, indicating unit cell contraction upon flash cooling. Second, the 
mosaicity (long-range order) of crystals analyzed on-chip was nearly an order of magnitude 
lower (better order) compared to other high-resolution RC structures crystallized in LCP.48,49 
Higher mosaicity (poorer order) is typically related to contraction of the unit cell caused by flash-
cooling to cryogenic temperatures.50,51 Availability of low-mosaicity crystals and non-cryogenic 
Figure 3.7:  A. A photograph of an RC crystal grown in a well plate and mounted in a loop. The 
crystal is located within the red circle indicating the footprint and the location of the X-ray beam. B. 
Although the crystal is difficult to see, its presence is confirmed by the characteristic diffraction 
pattern. The diffuse background scattering ring is due to the loop and the cooled mesophase. The 
green circle corresponds to the resolution of 2.45 Å. 
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data collection facilitated by the on-chip approach reported here may be highly beneficial for 
time-resolved protein crystallography.52  
Root mean square deviation (RMSD) comparisons revealed noticeable non-uniformly 
distributed deviations in the positions of backbone alpha-carbons in our RC structure compared 
to both available cryo-structures48,49 (Figure 3.5D, Table 2). The greatest deviations were 
located along the hydrophilic chains at the periplasmic and cytosolic sides of the protein (RMSD 
= 0.45 Å, Table 3.2) and were as large as 2 Å at residues 268-271 of the L-subunit (Figures 
3.5D, 3.8). The hydrophobic chains embedded within the lipid bilayer showed a significantly 
smaller deviation (RMSD = 0.28 Å, Table 2). Conversely, the RMSD values for superimposed 
cryogenic RC structures did not exceed 0.23 Å anywhere (Table 3.2). The overall RMSD of 
0.36-0.37 Å between the RT and the cryogenic structures was in the range reported for 
independent structure determinations of an identical protein53 (Table 3.1).  
Figure 3.8: (A) Sample electron density map at a resolution of 2.5 Å (σ = 1.0) showing residues 24-
28 of the L-subunit of the RC complex. (B-F) Visualization of RMSD calculations between the room 
temperature structure solved on-chip and a cryogenic structure (PDB ID: 2GNU).  RMSDs were 
calculated by location of α-carbon of each residue in the (B) M-subunit, (C) H-subunit, (D) L-subunit, 
(E) hydrophobic section, and (F) hydrophilic sections.  Residues colored in grey were not included in 
the RMSD calculation 
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For soluble proteins, cryo-cooling has been shown to affect mechanistically relevant side-
chain conformations and, in extreme cases, backbone conformations.50,51 Similar analyses for 
LCP-crystallized membrane proteins are largely unavailable because of the difficulties of 
Table 3.1: Crystallographic dataa and refinement statistics
 4TTQ (On-chip) Cryogenic (well plate) 
Unit cell dimensions a = b = 102.5     c = 239.9 a = b = 99.8     c = 232.7 
Space group P42212 P42212 
Resolution (Å) 50 - 2.50 50 - 3.50 
No. unique reflections 45,251 63,325 
Completenessb 95.8% (94.7%) ~93% 
Redundancyb 4.0 (3.2) 4.5 
Mosaicity (deg.) 0.06 - 0.09 1.19 
I/σb 10.0 (3.0) 1.75 
Rsymb 0.165 (0.628) 0.218 
# of frames 115 150 
No. atoms   
   Protein 6468  
   Water 162  
   Hetero 460  
Refinement   
   Rwork 0.180  
   Rfree 0.229  
Ramachandran statistics  
   Most favored 97.1%  
   Allowed 2.8%  
   Disallowed 0.1%  
 Protein Water Hetero Overall  
Average B-factors   
  Main chain (Å2)    34.6  
  Side-chain (Å2)    37.1  
  All (Å2) 35.9 36.8 31.9 35.6  
a Merging of small data sets from multiple crystals analyzed on-chip at room temperature 
b Values in parentheses indicate values for the highest resolution shells 
 
 
Table 3.2: Root-mean square deviations (RMSD) for structure comparison  
Structures RMSDa 
Target 1 Target 2 
All 
(833 
Cα) 
H-
Chain 
(250 
Cα) 
L-Chain
(281 
Cα) 
M-
Chain 
(302 
Cα) 
Hydrophobic
(438 Cα) 
Hydrophilic 
(395 Cα) 
L 264-275
(12 Cα) 
4TQQb 1OGVc 0.36 0.39 0.32 0.29 0.27 0.44 0.62 
4TQQ 2GNUc 0.38 0.39 0.35 0.29 0.28 0.45 0.69 
1OGV 2GNU 0.19 0.22 0.18 0.18 0.17 0.23 0.24 
a Measured in angstrom (Å).  RMSD calculated between alpha-carbons of target 1 and target 2 in PyMOL using 
the super function. 
bProtein Data Bank identification tag for on-chip (this work) structure 
cProtein Data Bank identification tags for cryogenic RC structures 
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obtaining RT crystal structures that require screening of a larger number of crystals, as 
highlighted in the impressive recent study of a human membrane protein under non-cryogenic 
conditions.54,55 While the transmembrane chains of the proteins are likely to be constrained by 
the membrane-like LCP environment, hydrophilic segments may undergo significant 
conformational changes upon flash-cooling, as also observed by Liu et al.54 These changes may 
be of importance for mechanistic studies and for protein docking, and the analysis of LCP-grown 
crystals under near-physiological temperatures, as enabled by our on-chip approach, may 
provide new insights into these phenomena.  
3.5 Conclusions 
In summary, we demonstrated the first X-ray transparent microfluidic chip for LCP crystallization of 
membrane proteins and subsequent on-chip X-ray diffraction data collection of multiple crystals on a 
single chip at room temperature for protein structure determination. We validated our approach by 
crystallizing a membrane protein, photosynthetic reaction center, and solving its structure to a resolution 
of 2.5 Å. The chip automates metering and sample formulation, eliminates manual mesophase handling, 
and reduces the amount of sample per trial ~7-fold compared to similar macroscale protocols,27,28 and ~3-
fold compared to standard protocols with pre-mixed mesophase.8,56 In situ X-ray data collection on 
multiple crystals obviates cumbersome manual harvesting of fragile protein crystals. These features make 
our chips a valuable tool for the analysis of membrane proteins by providing a facile route to crystal 
structures and potentially to time-resolved studies of LCP-embedded proteins. For example, our on-chip 
analysis of RC revealed conformational flexibility in its hydrophilic chains at RT. 
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CHAPTER 4 
High-throughput In Meso Crystallization Screening 
and Optimization of Membrane Proteins*
4.1 Introduction 
To trigger crystallization in lipidic cubic phases (LCP, or in meso crystallization), a multi-
component precipitant mixture of salts and other additives must be introduced into a protein-
laden mesophase.1 Unfortunately, protein crystallization conditions cannot be determined a 
priori, thus requiring extensive screening of hundreds to thousands of potential precipitant 
mixtures to find one that yields diffracting crystals.2,3 Further, to obtain crystals that diffract to 
atomic resolution, crystallization conditions must also be optimized through fine-gradient re-
screening of crystallization conditions4,5 and precipitants6. Unfortunately, the in meso 
crystallization method is tedious: the preparation of high viscosity protein-laden lipidic 
mesophases requires specialized tools and manual expertise for precise handling and 
dispensing, which complicates the set-up and repeatability of high-throughput screens and 
optimization at nanoliter volumes. Further difficulties arise after crystallization when crystals are 
usually physically transferred by the operator to a synchrotron-compatible holder and then flash 
frozen for X-ray analysis, a process which may damage the crystal and decrease the quality of 
X-ray diffraction data.7,8 
For traditional in meso crystallization experiments, several microliters of protein and lipid are 
mixed in coupled-syringes to form a highly viscous protein-laden mesophase. A protein-to-lipid 
ratio of 2:3 is typically selected from the temperature-composition diagram of lipid in water to 
form a stable cubic mesophase at room temperature for crystallization. In multicomponent 
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crystallization mixtures of lipid, protein, salts, detergents, and other additives, the mesophase 
behavior can change and ratios other than 2:3 may be ideal for stable cubic phases and 
crystallization, and in extreme cases unexpected phases will form, such as sponge phases.9–11 
In a few reports, other mixing ratios, formulations, and variant in meso methods have 
demonstrated successful crystallization: a reaction center was crystallized by overlaying protein 
over lipid for passive mixing by diffusion at a 2:1 protein-to-lipid ratio;12 a separate effort 
demonstrated passive mixing followed by controlled dehydration of the mesophase for 
crystallization.13 These methods showed that (1) crystallization-compatible mesophases can be 
formed reliably by passive mixing rather than coupled-syringe mixing, and (2) crystallization 
success can be affected by mesophase formulation and mesophase/protein mixing ratio, 
probably by influencing the amounts of protein and detergent incorporated in the same volume 
of mesophase. 
State-of-the-art methods for high-throughput screening and optimization of in meso 
crystallization often rely on robots to dispense mesophase boluses.14,15 The most common type 
of well-plates for crystallization with robots are hermetically-sealed glass-sandwich 
crystallization plates. Glass-sandwich plates are incompatible with in situ X-ray analysis, and the 
high viscosity of the mesophase plus the need to cut through the glass-sandwich plate to gain 
access to each crystallization well requires manual expertise to harvest the crystals, and is time-
consuming.14,16 Recent reports demonstrate in meso in situ X-ray crystallography by replacing 
glass plates with thin layers of either cyclic olefin copolymer (COC)17 or Mylar18, both materials 
with low background scattering and high transmission for X-rays. While a significant step 
forward for high-throughput in meso screening, the use of these X-ray transparent plates still 
relies in many cases on dispensing robots which perform crystallization in mesophases as small 
as 30–40 nl. 
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As an alternative approach, several microfluidic devices have successfully addressed 
formulation of in meso crystallization trials. The first microfluidic devices for in meso 
crystallization formulated mesophases by passive mixing in droplets19 or chaotic mixing in 
microchambers.20 Both microfluidic approaches successfully yielded diffraction quality crystals, 
but the chips were an additional barrier to solving crystal structures as neither approach 
facilitated the process of crystal harvesting and X-ray analysis. To overcome this hurdle, a set of 
design principles were developed to build thin X-ray transparent microfluidic devices for crystal 
growth and in situ X-ray analysis.21,22 For X-ray diffraction experiments, the entire chip was 
mounted in front of an X-ray source, and the resulting crystal structures had very good 
resolution and mosaicity, two parameters that often suffer as a result of crystal harvesting. An X-
ray transparent device for in meso crystallization for passive mixing of protein and lipid was 
developed and validated by crystallizing and solving a high-resolution structure of the 
membrane protein, photosynthetic reaction center (Section 3.4).23 Formulation was automated 
by loading protein directly on-top of lipid to create a large, open-interface for mixing by diffusion; 
the subsequent addition of a precipitant into a connected adjacent well triggered crystallization. 
The application of these in meso devices as all-in-one mesophase formulation, crystallization, 
and X-ray diffraction tools for routine experiments, such as screening and optimization, is limited 
by scale (50–70 nL mesophases in each well, 12 well arrays). 
Building on these prior efforts, this project overcomes the scaling limitations of X-ray 
transparent in meso crystallization devices and demonstrates their applicability in routine 
crystallization experiments, specifically high-throughput condition screening and optimization. 
First, the limitations of scale-down were addressed to efficiently utilize precious membrane 
protein solution. To achieve this, a capillary-valve strategy was developed to deliver as little as 8 
nL of membrane protein (to form 13 nL of protein-laden mesophases) into open-interface 
crystallization wells. Second, the limitations of scale-out were addressed by designing densely-
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packed microfluidic arrays to screen up to 192 potential crystallization conditions and 
combinatorial microfluidic arrays to generate 16 fine-gradient condition variants to optimize 
crystallization conditions. To validate the effectiveness of these microfluidic devices for routine 
crystallization experiments, they were used: (1) as high-throughput screening tools to identify 
new crystallization hits of three membrane proteins with limited or no structural data: quinol-
dependent nitric oxide reductase (qNOR), cytochrome bo3 oxidase, and the LM-dimer of 
photosynthetic reaction center, and (2) as crystallization optimization tools to increase the size 
and diffraction quality of crystals of a reaction center mutant, L223SW, from which the structure 
was solved on-chip to a resolution of 3.5 Å. 
4.2 Materials and methods 
Chemicals. For the experiments described here, we used screening kits (Cubic Screen 96-well 
screening kit from Emerald Biosystems, now distributed as Wizard Cubic Screen from Molecular 
Dimensions, Altamonte Springs, FL), monoolein (1-Oleoyl-rac-glycerol) and cholesterol (Sigma–
Aldrich, St. Louis, MO), polydimethylsiloxane (PDMS) (RTV-615 from Momentive Performance 
Adhesives, Waterford, NY), negative photoresists (SU-8 25 and SU-8 2050 from MicroChem 
Corporation, Newton, MA), cyclic olefin copolymer films (COC) (Grade 6013, 2 mil from TOPAS 
Advanced Polymers, Florence, KY), silanizing agent (tridecafluoro-1,1,2,2-
tetrahydrooctyl)trichlorosilane from Gelest, Inc., Morrisville, PA), and epoxy (Conapoxy FR 1080 
from Cytec Industries, Woodland Park, NJ). All other salts, precipitants and solvents were 
purchased from Sigma–Aldrich and Hampton Research and used without further purification. 
Preparation of protein samples. Photosynthetic reaction center (L223SW) and LM dimer were 
produced through site-directed mutagenesis in the pUCLHRC plasmid as described 
previously.24 pUCLHRC is based on the commonly used cloning vector pUC19 and has the 
photosynthetic puh and puf operons integrated as a 5kb BamHI/EcoRI fragment. After verifying 
the mutation with DNA sequencing, the mutated fragment was cleaved and incorporated to 
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vector pATP19P25, which, unlike pUC19 based plasmids, can be maintained in Rhodobacter 
sphaeroides. This mutated plasmid was then transferred to the R. sphaeroides strain ∆LHRC 
(knockout of reaction center and both light harvesting complexes) via conjugation. Transformed 
R. sphaeroides was cultured in Sistrom medium supplemented with 0.5% yeast extract. 
Expression of the photosynthetic reaction center was induced automatically at high cell density 
under low oxygen tension. The purification of mutant photosynthetic reaction center follows the 
same protocol for the wild type26. Starting with the purified bacterial photosynthetic reaction 
center which contains three subunits, the LM dimer core complex was prepared by precipitating 
the H subunit in the presence of lithium perchlorate and ethanol.27 Extensive dialysis against 10 
mM Tris, 0.03% LDAO (N,N-dimethyldodecylamine N-oxide) pH 8 was then carried out to 
remove these chaotropic agents. 
Cytochrome bo3 ubiquinol:oxygen oxidoreductase (cytochrome bo3 oxidase) was 
overexpressed by IPTG (isopropyl β-D-1-thiogalactopyranoside) induction in E. coli strain 
C43(DE3) transformed with plasmid pETcyo. Bacteria were cultured in M63 minimal medium at 
37 °C as previously reported.28 When the cell density reached an OD600 of ~0.6, 0.5 mM IPTG 
was added to the culture. After 4–6 h of induction to allow protein expression, cells were 
harvested by centrifugation at 5,000 g for 20 min at 4°C. Cells were then disrupted with a 
French press. After 10 min of low speed spin at 5,000 g to remove cell debris, the cytoplasmic 
membrane was pelleted at 180,000 g for 4 h at 4°C. The membrane was then resuspended in 
50 mM potassium phosphate pH 8 and solubilized with 1% DDM (n-dodecyl β-D-maltoside), 
followed by 1 h centrifugation at 180,000 g at 4°C to remove insoluble membrane fractions. The 
supernatant containing bo3 oxidase in DDM micelles was loaded onto a Ni-NTA affinity column. 
After washing with 5 column volumes of 10 mM imidazole, cytochrome bo3 oxidase was eluted 
with 50 mM imidazole. Extensive dialysis in either 50 mM potassium phosphate, 0.05% DDM or 
20 mM Tris-HCl, 0.7% n-octyl-β-D-glucoside (OG) was performed to remove imidazole. 
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Quinol nitric oxide reductase (qNOR) was prepared using the 2,200 base pair qNOR gene 
from Peresephonella marina which was amplified from genomic DNA using PCR, cloned into 
the plasmid pET-22b (Novagen), and overexpressed by IPTG induction in E. coli strain 
C43(DE3). Bacteria were cultured in LB media at 37°C while shaking at 200 rpm. Once the 
cultures reached an OD600 of 0.7, 1 mM IPTG was added to the culture. Cells were harvested 
after 4 h of induction using centrifugation at 5,000 g for 10 min at 4°C, and broken by passing 
the cell suspension through a Microfluidizer three to four times at a pressure of 80,000 psi. The 
membrane fraction was collected by centrifugation of the disrupted cell membranes at 180,000 
g for 4 h at 4°C. Isolated membranes were resuspended in buffer containing 100 mM Tris-HCl 
pH 8, 100 mM NaCl and solubilized with 1% DDM. Insolubilized membrane was pelleted with a 
30 min centrifugation at 180,000 g. The supernatant containing qNOR was applied to a Ni-NTA 
affinity column. The resin was washed in the buffer containing 50 mM imidazole and 0.05% 
DDM, then the protein was eluted in the buffer containing 100 mM imidazole and 0.05% DDM. 
The protein was concentrated using 100 kDa molecular weight cutoff centrifugal filter units 
(Millipore) and dialyzed against 100 mM Tris-HCl pH 8, 100 mM NaCl, 0.05% DDM, and 10% 
glycerol. 
For all proteins, small aliquots (<10 µL) of the protein sample were flash-frozen in liquid 
nitrogen and stored at –80°C until use. 
Flash-induced optical spectroscopy for reaction centers. Flash-induced optical 
spectroscopy was carried out with an in-house designed apparatus. The saturating excitation 
light pulse, which initiates electron transfer within the photosynthetic reaction center, comes 
from a Xenon flash lamp controlled by a LabJack U3-LV via TTL signal. The continuous 
measuring beam from a 12 V tungsten lamp first goes through a Bausch & Lomb 
monochromator, then passes through the sample cuvette. The transmitted fraction was 
measured with a photomultiplier as voltage. This signal was recorded by a PicoScope (Model 
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4424) as a function of delay after the excitation pulse and converted into absorbance using 
value prior to the excitation pulse as a reference. 
Synchrotron X-ray diffraction data collection: X-ray diffraction data were collected at APS 
(Advanced Photon Source) synchrotron, Argonne National Laboratory, specifically beamlines 
21-ID-F, LS-CAT (Life Sciences Collaborative Access Team) and 23-ID-B GM/CA (General 
Medical Sciences and Cancer Institutes Structural Biology Facility). In-line microscopes aided in 
focusing on crystallization wells and centering on crystals. At 21-ID-F, a 20 x 20-µm microbeam 
with a wavelength of 0.9795 Å was used, and data were collected in 0.5–1° steps with 1–2 s 
exposures and sample-to-detector distance between 200–500 mm with a MARmosaic 300 
detector. At 23-ID-B, data were collected in 0.2–0.4° steps with 0.2–0.4 s exposures and a 
sample-to-detector distance between 400–500 mm with a Pilatus 6M detector. All data were 
collected at room temperature, and an on-chip serial crystallography approach was utilized to 
mitigate the effect of radiation damage as demonstrated in prior work.23 
Data reduction and structure determination for L223SW: From the 50 crystals of L223SW 
mutant, X-ray data from 19 crystals that diffracted to a maximum of 3.2 Å were used for 
structure determination. HKL2000 software was used for indexing, refinement, integration, and 
scaling multiple data sets together (HKL Research Inc.).29 Molecular replacement, structure 
building, and refinement were done using the Phenix suite of programs.30 Molecular 
replacement was performed with Phaser using PDB structure 4TQQ as a model.23 Ligands 
bound to the structure were identified in the electron density and built into the final model. 
Electron density maps were displayed and compared using PyMOL. 
Fabrication of high-throughput X-ray transparent microfluidic chips. Microfluidic chips 
were fabricated using a strategy adapted from previous work.23 For a full description, see 
Chapter 3. Briefly, patterned COC substrate layers were fabricated by hot embossing 50 µm 
thick sheets of COC with a high temperature epoxy master mold in a laminating press (Carver). 
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Photoresist-on-silicon master molds were fabricated by photolithography using transparency 
photomasks (Figure 4.1). Polydimethylsiloxane (PDMS), an elastomeric thermoset, was spin-
coated on photoresist-on-silicon master molds to fabricate thin, patterned PDMS fluid and 
control layers by soft lithography. The chip layers were assembled through a combination of 
irreversible and reversible bonds. A blank COC layer was irreversibly bonded to the PDMS 
control layer by activating the surfaces with an atmospheric plasma treatment (Harrick) and then 
bringing them into direct contact. This COC–PDMS control layer was then irreversibly bonded to 
the PDMS fluid layer by a thermal bonding31 to form a COC–PDMS–PDMS three-layer 
assembly (TLA). Prior to crystallization experiments, the compartments in the patterned COC 
substrate layer were filled with lipid. The crystallization wells in the TLA were aligned to the lipid 
compartments and reversibly bonded by surface adhesion to complete the construction of the 
Figure 4.1: Photomasks for three designs used for screening and optimization.  Each device contains
three patterned layers: the control layer, the fluid layer, and the lipid compartment layer. A fourth
photomask for each design, lipid filling layers, was used to generate ancillary chips to deposit ~5 nL of
lipid into each lipid compartment. Photomasks were printed at 10,000 dpi on a Mylar transparency film
(Fineline Imaging). 
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chip. Vacuum interconnects were fabricated from PDMS blocks attached to PTFE tubing to 
facilitate vacuum actuation. 
4.3 Design and operation of in meso crystallization wells and arrays 
Design of in meso crystallization well. The design goal was to automate the sequential 
mixing of three components—protein, lipid, and precipitant—in a compact and modular well for 
scale-out into microfluidic arrays (Figure 4.2b). Individual wells for formulation of in meso 
crystallization trials rely on passive mixing, as demonstrated in prior work (Chapter 3).23 In a 
microfluidic well, protein solution was layered on top of dry lipid in the chip’s substrate layer 
(Figure 4.2a, c) for passive formulation of a protein-laden mesophase by mixing across a large 
Figure 4.2: Architecture of a single microfluidic in meso crystallization well. (a) Optical micrograph of a
single crystallization well during a crystallization experiment. Protein and precipitant meet at a mixing
interface in an open-ended capillary valve for passive mixing by free interface diffusion. (b) Photograph of
a microfluidic array chip for in meso crystallization, showing a chip filled with protein (red solution) and
precipitants (blue, green, yellow, and clear solutions). (c) Exploded schematic of a single crystallization
well. X-ray transparency is achieved by construction with <200 µm of low-scattering materials. (d) Inset of
the open-ended capillary valve, highlighting key optimization parameters indicated with capped red lines
or red angles. Experimental studies of width (w), expansion angle (θ), and length (L) resulted in an
optimal valve geometry for high-throughput chips.  
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lipid-protein interface. After protein-lipid mixing, the protein-laden mesophase becomes very 
viscous and remains immobile. During mixing, a concentration gradient may form into the 25 µm 
depth of the lipid layer, although this effect is difficult to visually observe with light microscopy. 
Next, a precipitant solution was filled in the other half of the well. The two half-wells (protein/lipid 
and precipitant) meet in a 75 µm-wide ‘S’-shaped channel where mixing of the protein-depleted 
solution and precipitant occurs by diffusion across a liquid–liquid interface. As the precipitant 
mixes with the protein-depleted solution, it begins to diffuse into the protein-laden mesophase to 
trigger crystallization. While mixing of precipitant into the mesophase is expected to be complete 
within a few minutes, the mesophase and precipitant reservoir stay in contact indefinitely across 
the normally-open capillary valve to ensure mixing to completion.  A multilayer hybrid chip 
architecture of two polymers is required for chip functionality: (1) elastomeric 
polydimethylsiloxane (PDMS) for the fluid layer and control layer, which enables the use of 
normally-closed, vacuum-actuated valves for filling and fluid routing, and (2) rigid, impermeable 
cyclic olefin copolymer (COC), which enables long-term incubations (>1 month) for crystal 
growth. Further, the chip construction of thin PDMS layers (X-ray path length: ~20 µm) 
sandwiched between two COC layers (X-ray path length: ~75 µm) impart the chips with X-ray 
transparency for in situ crystal diffraction experiments (Figure 4.2c).21,23 
In contrast to prior work, this approach addresses the challenges of scale-down (volume of 
reagents) and scale-out (number of tests) in the design of the chip. To automate high-
throughput screening, a large number of wells are needed on a single chip. To accomplish this, 
the footprint of each microfluidic well was scaled-down and re-designed to fit modularly in dense 
arrays. Features in the vacuum control layer were reconfigured for facile operation: in these 
scaled-out chips, as few as 2 control lines automate filling and mixing in every well. Additionally, 
the filling strategy was modified to use an open-ended capillary valve to optimize handling 
volumes as small as 8 nL. Capillary valves are routinely employed in the field of centrifugal 
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microfluidics,32 but in this report, the strategy is adapted to vacuum-actuated microfluidics. The 
open-ended capillary valve balanced the vacuum-induced force that drives dead-end filling with 
resistance to flow in a narrow microfluidic channel. Test arrays that varied the width, length, and 
expansion angle of the open-ended capillary valve were used to determine an optimal valve 
geometry, and after testing, a long ‘S’-shaped channel resulted in the best performance (Figure 
4.2d, 4.3). 
Microfluidic arrays were built using these wells to address two challenges in membrane 
protein crystallization: high-throughput screening for crystallization hits (Section 4.4), and 
optimization of crystallization hits (Section 4.5). 
Deposition of lipid into the COC substrate. Lipid was filled as described in Chapter 3 with 
two key differences to address the scale and throughput for screening and optimization. First, 
up to 192 lipid wells were filled in parallel using a single lipid-filling chip. Second, substrates held 
~5 nL of lipid due to the reduction in preparative scale.  After filling and solidifying the lipid, the 
lipid-filling chip was removed from the substrate, and each crystallization well of the TLA was 
Figure 4.3: Microfluidic test arrays to determine optimal characteristics for an open-ended capillary valve.
(a) Schematic of a filled protein compartment (bottom, green) separated from the precipitant compartment
(top, empty) by an ‘S’-shaped capillary valve. The width (w), length(L), and expansion angle (θ) of the
capillary valve are noted. (b) Optical micrographs from testing of each valve length, width, and expansion
angle. Greater expansion angles and longer channel lengths had the most significant improvements on
creating resistance to flow and thus fluid retention. The final valve geometry combined these elements
into a compact design with a long, ‘S’-shaped channel and an expansion angle greater than 90°. 
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aligned over each lipid-filled chamber in the substrate to complete the assembly of a full 
crystallization device. 
Setting up crystallization screening and optimization trials on-chip. A vacuum source, a 
vacuum interconnect, and a pipette were required to operate microfluidic screening and 
optimization chips. First, 1–3 µL of solution were pipetted onto each protein inlet. A vacuum 
interconnect (a small PDMS block and tubing attached to a vacuum pump that reversibly sealed 
to the chip’s surface) was then placed on a protein-fill vacuum port, initiating liquid filling by 
simultaneously opening normally-closed microvalves and displacing air with protein solution. 
Vacuum actuation of the control layer creates a pressure gradient in the fluid layer due to the 
permeability of air through PDMS. Protein and precipitant solutions completely filled into a dead-
end as air was withdrawn. Protein filling typically completed within 2 minutes, and the protein 
solution only filled the protein chamber up to the open-ended capillary valve (Figures 4.2, 4.3). 
Lipid and protein mixed passively by diffusion during a 4-8 h incubation. Next, 1 µL of each 
precipitant was pipetted onto each precipitant inlet and filled by vacuum actuation. Precipitant 
filling was typically completed within 5 minutes. The protein and precipitant inlets were then 
sealed with crystal-clear tape, and the entire chip was placed in a sealed Petri dish with a 
microcentrifuge tube containing 500 µL of water. Chips were stored in a 20°C incubator for up to 
6–8 weeks. Crystallization was monitored with a microscope (Leica MDG33, DFC295) 1, 2, 4, 
and 7 d after filling, and then every three days afterward. 
4.4 Screening of novel membrane proteins: cytochrome bo3 oxidase, 
qNOR, and LM-dimer 
To facilitate the discovery of suitable conditions for growing diffraction-quality crystals, dense 
microfluidic arrays of up to 192 wells for in meso crystallization were designed (Figure 4.4a). 
These high-throughput devices mix a single membrane protein sample with up to 48 different 
precipitant solutions. Membrane protein solution fills through two inlets into 192 protein 
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compartments of varying sizes. Precipitants fill through 48 inlets into sets of 4 precipitant 
compartments. Prior to filling with membrane protein and precipitants, ~5 nL of monoolein was 
Figure 4.4: High-throughput screening chips for membrane protein crystallization. (a) Designs for 192-
well (left) and 48-well (right) screening chips. Fluid introduced through protein and precipitant ports mix 
to generate 192 unique conditions. (b) Variable protein:lipid ratios generated in high-throughput 
screens. As indicated in the table, the amount of lipid for mesophase formulation remains constant 
while the variable size of protein compartments generates a linear gradient of protein concentrations. 
Each precipitant mixes with four different mesophases for extensive screening. (c) Tabulated 
screening results for qNOR, screened at 20 mg/mL with Cubic Screen. 96 conditions (A1—H12) were 
screened in high-throughput chips. Scores are indicated with colors and numbers: red (0–1) and grey 
(2–3) for a negative result, yellow (4–6) for optimization candidates (low quality crystals, crystallites), 
and green (7–9) for diffraction ready crystals (not observed in shown qNOR screen). (d) 
Representative crystallization screening results and scores for qNOR, cytochrome bo3 oxidase, and 
the LM-dimer (3 conditions each) as visualized on-chip with light or cross-polarized microscopy.  
Scale bar: 100 µm 
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deposited into compartments in the patterned COC substrate layer,23 after which the TLA was 
aligned and reversibly sealed to complete the assembly of high-throughput chips (Figure 4.2c). 
To begin a high-throughput screening experiment, 2.5 µL of membrane protein solution was 
pipetted onto each protein inlet. Next, vacuum actuation of control lines 3 and 4 (Figure 4.4a) 
initiated filling of 8–17 nL of protein solution into each protein compartment directly on top of the 
monoolein. After a 4 h incubation to allow protein–lipid mixing by passive diffusion, 1 µL each of 
48 different precipitant solutions were pipetted onto the precipitant inlets. Vacuum actuation of 
control lines 1 and 2 initiated filling of precipitants into each precipitant compartment. Chips 
were incubated for up to 8 weeks and regularly monitored for crystallization with polarized light 
microscopy. As previously discussed, the protein-to-lipid ratio (2:3 in coupled syringes, 2:1 for 
passive mixing) used traditionally in screening is derived from a binary monoolein–water phase 
diagram, the behavior of which may significantly change upon addition of salts, detergents, and 
precipitants. On microfluidic chips, mesophase mixing occurs independently in each well. To 
enhance and widen the extent of screening, chips are designed to vary the protein-to-lipid ratio 
from one well to the next based on the size of the protein compartment. In contrast to off-chip 
work where mesophases are usually prepared in bulk with coupled-syringes and to prior on-chip 
work where protein-to-lipid ratio was maintained at 2:1, high-throughput chips screen protein-to-
lipid ratios from 1.5:1 to 3.3:1 for each precipitant (Figure 4.4b). To screen the same conditions 
via passive mixing in meso crystallization in a well plate (with pre-deposited lipid), 284 individual 
pipetting actions would be required, while the microfluidic approach presented here both 
conserves protein sample and reduces the burden on the experimenter by requiring 50 pipetting 
actions. 
To validate the screening capabilities of these high-throughput microfluidic chips, three 
membrane proteins that were not previously crystallized in meso were screened: (1) quinol nitric 
oxide reductase (qNOR) from Persephonella marina, (2) cytochrome bo3 oxidase from 
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Escherichia coli, and (3) the LM-dimer of reaction center from Rhodobacter sphaeroides. 
Protein concentrations ranged from 5–20 mg/mL for each of the proteins. Precipitants from an in 
meso compatible screening kit, Cubic Screen (Emerald Bioscience), were used.33 Chips were 
observed with optical and cross-polarized microscopy at scheduled intervals after the chips 
were set-up. Each well was evaluated and assigned a score using an in meso crystallization 
scoring system14: scores from 0–1 indicated incompatibility with the mesophase, 2–3 indicated 
no notable crystal hit, 4–6 indicated a hit that may lead to crystals upon optimization, and 7–9 
indicated crystal growth. For each protein, on-chip screening was conducted at variable protein 
concentrations and variable precipitant concentrations. Extended experimental details are 
included in the Supporting Information. 
During screening with 192 well chips, each condition was sampled in duplicate. Using just 
two chips, 96 Cubic Screen conditions could be screened with one protein solution condition, 
and 4 chips were used to complete an entire screen in duplicate. After the first pass for 
screening, Cubic Screen conditions were diluted with MilliQ water in a 1:1 ratio and repeated. 
Crystallization hits (Table 4.1) were tested for diffraction, although no indexable diffraction 
patterns were identified. Several crystallization hit conditions for each protein were selected for 
optimization. First, the Cubic Screen hit condition was diluted with MilliQ water in ratios of 1:1, 
1:2, 1:4, and 1:6. Further, each component of the crystallization hit conditions (pH and 
concentrations of buffer, salt, and precipitant) were systematically varied. Despite extensive 
screening and optimization attempts on crystallization hits, crystals did not yield high-quality 
diffraction, indicating that an expanded set of chemical compositions must be surveyed to grow 
crystals for structural studies. 
Each crystallization condition was evaluated using a scoring system developed by Caffrey et 
al.14 Each crystallization well was evaluated as a whole and assigned a score. Briefly, a score of 
0–3 indicated a negative result, ranging from an incompatible lipidic phase (0) to a protein 
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precipitate (3). Scores from 4–6 indicated a result for further optimization, ranging from a 
birefringent precipitate (4) to microcrystals (6). Higher scores, 7–9, indicated positive 
crystallization results, either 1-D crystals (7), 2-D crystals (8), or well-defined 3-D crystals (9). 
For some protein–detergent combinations, high concentration samples prepared in 
centrifugal concentrators resulted in a persistent bulk birefringent phase when observed through 
crossed polarizers. Birefringence indicates that a stable cubic phase has not formed, and the 
likelihood of crystallization is low. In previous literature, high detergent concentrations have 
been shown to destabilize cubic phases.34 This is particularly prevalent with some detergents 
commonly used in crystallization, including DDM and OG, which were used in this study to 
stabilize qNOR and cytochrome bo3 oxidase, as they either form large protein–detergent 
complexes that not pass through a centrifugal concentrator or as they have a high critical 
micelle concentration.35  Passive mixing approaches facilitate screening with lower protein 
Table 4.1: High-throughput screening hits1
Membrane protein sample Crystallization condition hits 
qNOR, 5–10 mg/mL 
100 mM Tris-HCl pH 8.0,  
100 mM NaCl,  
0.05% DDM 
20% (w/v) PEG 1000,  
100 mM HEPES/ NaOH pH 7.5,  
200 mM Magnesium chloride 
30% (w/v) PEG 8000,  
100 mM Sodium cacodylate/HCl pH 6.5,  
200 mM Calcium acetate 
Cytochrome bo3 oxidase, 5–10 mg/mL 
50 mM Potassium phosphate pH 8, 
0.05% DDM 
2.5 M NaCl,  
100 mM Sodium citrate/citric acid pH 5.5, 
200 mM Magnesium chloride 
Cytochrome bo3 oxidase, 5–10 mg/mL 
20 mM Tris-HCl pH 8,  
0.7% OG 
2.5 M NaCl,  
100 mM MES/NaOH pH 6.0,  
200 mM Lithium sulfate 
20% (w/v) PEG 1000,  
100 mM HEPES/NaOH pH 7.5,  
200 mM NaCl 
LM-dimer, 5–20 mg/mL 
10 mM Tris pH 7.8,  
280 mM NaCl,  
0.03% LDAO  
1 M HEPES pH 7.5,  
1.15 M (NH4)2SO4,  
12–15% Jeffamine M-600 
1 All 96 conditions from Cubic Screen were tested, and those producing crystals are 
listed here 
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concentrations due to a concentrating effect during the mixing process.12 Compared to initial 
screens, reduced concentrations (qNOR: <10 mg/mL, cytochrome bo3 oxidase: <15 mg/mL) 
yielded stable cubic phases and successful crystallization screening. Several crystallization hits 
were successfully identified for the target proteins within 14 d, and representative results and 
screening data are shown (Table 4.1, Figure 4.4c, d).  
Next, diffraction quality of the hits discovered for each membrane protein was evaluated. 
Screening chips were directly mounted without modifying the goniometer at beamlines 21-ID-D 
or 23-ID-B for room-temperature X-ray diffraction experiments. To accomplish this, a magnetic 
cap mount was modified with a tube with a thin slit and a set-screw to hold the microfluidic 
chips. Crystal hits were identified and targeted via an on-axis video microscope and sequentially 
probed with X-rays: (1) qNOR crystal hits yielded either no diffraction or weak scattering rings, 
(2) cytochrome bo3 oxidase crystal hits yielded weak, low resolution diffraction (<12 Å), and (3) 
LM-dimer crystal hits yielded no identifiable diffraction. Unfortunately, optimization of these hits 
did not yield crystals with better diffraction, indicating that either (a) a wider range of chemical 
compositions must be evaluated to uncover ‘good’ crystallization hits, or (b) these proteins or 
particular protein preparations (choice of buffer, detergents, and additives) are intractable and 
resistant to forming high-quality crystals. A more complex crystallization device could broaden 
the variety of crystallization conditions screened in parallel by either sampling more precipitant-
to-mesophase ratios, or by introducing on-chip serial dilutions36 to screen a fine-gradient of 
concentrations for each precipitant. Regardless, through successfully screening crystallization 
conditions, identifying new hits, and evaluating their diffraction with X-rays, this work 
demonstrates an automated high-throughput in situ approach for in meso crystallization 
screening with minimal sample consumption. 
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4.5 Fine-gradient optimization of crystallization conditions: L223SW 
and microbial rhodopsin 
Microfluidic optimization chips were developed to facilitate the optimization of poorly 
diffracting crystallization screening hits. These experiments sample a fine-gradient of protein 
and precipitant mixtures, based on the condition obtained in the initial trial, in fully combinatorial 
48-well arrays. On a single chip, 4 concentration or composition variants of a protein solution 
are mixed with 4 variants of a precipitant solution in all possible combinations. Four inlets for 
protein solution (P1–P4) fill the protein compartments in each of 4 quadrants of the chip, while 7 
Figure 4.5: Optimization chips for membrane protein crystallization. (a) Design of a 48-well chip (left) 
and fluid filling scheme (right) for a crystallization optimization experiment. The mixing array formulates 
fully combinatorial in meso crystallization experiments for 4 different levels of both protein and 
precipitant, aiding the search for diffraction-quality crystals once proper precipitant components are 
discovered via screening. (b) (left) Photograph of on-chip optimization experiment for L223SW 
observed 10 d after set-up. (right) Representative optimization results from each condition formulated 
on a single chip. No crystallization was observed at low protein concentration, and many small crystals 
appeared at high protein concentration and low precipitant concentration. The best crystals were 
observed at higher protein concentrations (15, 20 mg/mL) and high precipitant concentrations (14—
15%). Scale bars: 100 µm 
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inlets for precipitant solutions fill the precipitant compartments (4 unique solutions, Ppt1–Ppt4) 
and formulate 16 unique combinations of in meso crystallization conditions in triplicate 
(Figure 4.5a). 
The parameters to be optimized (e.g., protein concentration, pH, precipitant concentration, 
additive concentration) are chosen and prepared off-chip. The operation of the chip is similar to 
the operation described above (Section 4.3) with a few small differences. To begin an 
optimization experiment, first 1 µL of each protein solution was pipetted onto each of the protein 
inlets. Next, actuation of control line 2 initiated filling of protein into the protein compartment 
directly on top of the lipid. After a 4-8 h incubation to allow protein–lipid mixing by passive 
diffusion, 1 µL of each of 4 precipitant variants were pipetted onto their respective inlets (Figure 
4.5a). Actuation of control line 1 initiated the filling of precipitant into each precipitant 
compartment. To perform the same optimization experiment for passive mixing in meso 
crystallization in a well plate (with pre-deposited lipid), 96 individual pipetting actions would be 
required, while the microfluidic approach presented here requires just 11 pipetting actions. 
Two proteins were used for testing and validating these optimization chips: a microbial 
rhodopsin18,37 from Haloquadratum walsbyi  and a photosynthetic reaction center mutant from 
Rhodobacter sphaeroides, denoted L223SW. Initial testing of crystallization and fluid flow for the 
optimization device were conducted with microbial rhodopsin, a photochemically active seven-
transmembrane α-helical protein with a covalently bound retinal chromophore. Upon mixing of 
protein and precipitant with known crystallization conditions (7.5 mg/mL in 50 mM MES pH 6.5, 
500 mM NaCl, 1% OG mixed with 7–10% Tacsimate pH 7, 20% PEG 3350), a birefringent 
mesophase formed. After 4 weeks of incubation with precipitant, the phase was no longer 
birefringent and microbial rhodopsin crystals ranging from 20–50 µm were observed on-chip.37 A 
coarse optimization was conducted with two protein concentrations (7.5 and 15 mg/mL) and 4 
variations of precipitant (7–10% Tacsimate), although significant changes in crystal size and 
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quality were not observed (Figure S4.6a, b). X-ray diffraction data were collected at room 
temperature, but the crystals were highly susceptible to radiation damage and rapidly discolored 
from purple to pale blue, indicating damage or displacement of the chromophore (Figure 4.6c). 
Prior to radiation damage, crystals diffracted to ~2.5 Å (Figure 4.6d). Due to the lengthy 
crystallization time and fragility of microbial rhodopsin crystals, validation of optimization chips 
was instead carried out with the L223SW mutant.   
The L223SW mutant was designed for fundamental structure–function experiments to study 
the mechanism of electron transport in photosynthetic reaction centers. The crystal structure 
and crystallization conditions are known for the wild-type protein, and we previously grew 
crystals on-chip and solved the structure for the wild-type reaction center (PDB: 4TQQ).23 As a 
Figure 4.6: On-chip crystallization experiments of microbial rhodopsin. (a) Optical micrograph of crystals
grown at 15 mg/mL microbial rhodopsin and precipitant containing 8% Tacsimate. (b) Optical micrograph
of crystals grown at 7.5 mg/mL microbial rhodopsin and precipitant containing 8% Tacsimate. (c) A 50 µm
hexagonal crystal (i) before X-ray exposure, observed with a light microscope, and (ii) after X-ray
exposure, observed using the in-line microscope at beamline 23-D-D. Green circles indicate beam size at
two exposure locations. (d) Sample diffraction pattern up to 2.5 Å at room temperature of microbial
rhodopsin collected on-chip. 
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starting point, crystallization was attempted with the condition used in prior work (15 mg/mL 
reaction center in 10 mM Tris pH 7.8, 280 mM NaCl, 0.05% LDAO mixed with 1 M HEPES, 1.15 
M (NH4)2SO4, 13% w/v Jeffamine M-600 adjusted to pH 7.5). However, this condition produced 
small crystals that diffracted only to 6 Å, while the wild-type crystals had diffracted to 2.5 Å. To 
obtain structure-quality crystallization conditions for L223SW, changes in protein concentration 
(5–20 mg/mL), pH (7.4–8.0), and precipitant concentration (Jeffamine M-600, 12–15% w/v) 
were analyzed with optimization chips (Figure 4.5b). Changes in pH either had a negative or no 
effect on crystallization. High concentrations of protein and low concentrations of precipitant 
resulted in small (~20 µm), poorly diffracting (~6 Å) crystals, while high concentrations of both 
protein and precipitant solutions resulted in the largest crystals (~60 µm) with good diffraction 
(~3.2 Å) (Figure 4.7c). The best diffracting crystals were grown with 20 mg/mL protein at pH 7.8 
Figure 4.7: (a) Work station at beamline 23-ID-D, Advanced Photon Source. Targeting cameras for
crystal centering are shown. On the left, a top-down low resolution camera for bringing the plane of the
chip into focus. On the right, an on-axis high resolution camera for crystal targeting. The L223SW crystal
pictured is ~50 µm in size. (b) An optimization chip mounted on the X-ray goniometer, enabling quick
crystal identification and targeting for serial crystallography. (c) An X-ray diffraction pattern from
L223SW, diffraction extends out past the 4 Å ring. Background scattering from the chip materials is
present between 6 and 10 Å. 
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using high concentrations of Jeffamine M-600 (14–15% w/v). 
Following a previously developed on-chip data collection strategy for room-temperature 
crystals (Figure 4.7),23 in situ data was collected from multiple crystals in small wedges and 
then merged together to minimize the effect of radiation damage on the structure. In total, 19 
crystals from a small range of conditions (15–20 mg/mL for protein, 14–15 % w/v Jeffamine M-
600) were selected to form an optimal dataset. Despite the small variations in chemical 
composition, the crystals had near identical lattice parameters (<0.5% variation) and a small 
variation in mosaicity. Interestingly, crystallization at 20 mg/mL L223SW and 15% w/v Jeffamine 
M-600 yielded the lowest mosaicity crystals and the highest quality of diffraction (3.2 Å). The 
crystal structure of L223SW was solved to a resolution of 3.5 Å (Table 4.2, PDB: 5V33). In the 
wild-type protein, a serine located in the L-subunit at position 223 facilitates the binding of a 
quinone (QB) molecule, which serves as the terminal electron acceptor for the reaction center. 
Both residue Ser223 and QB are resolved in the wild-type crystal structure (Figure 4.8a). In the 
mutant protein, the small polar residue Ser223, is replaced with tryptophan, a relatively large 
hydrophobic residue (Trp223, also denoted S223W). In the solved structure, Trp223 protrudes 
Figure 4.8: The secondary quinone (QB) binding pocket in the L-subunit of R. sphaeroides reaction 
center. (a) The binding pocket in the wild-type structure where QB, a ubiquinone-8 molecule that 
serves as the terminal electron acceptor is present. (b) The QB binding pocket in the L223SW mutant, 
where the mutated residue (serine to tryptophan) blocks the binding pocket, inhibiting the binding of 
QB. All 2FO—Fc maps are contoured to ±1σ. (c) Flash-induced spectroscopy of wild-type and mutant 
reaction centers. In the wild-type where QB is present, the backward electron transfer from QB- to the 
special pair of bacteriochlorophyll P+ has a lifetime of ~1 s. In contrast, in the mutant where QB is 
absent, the electron transfer from QA- to P+ has a lifetime of ~0.1 s. This spectroscopic measurement 
indicates that a functional QB is absent in the L223SW mutant.  
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into the binding pocket, which prevents QB from binding (Figure 4.8b). This structural 
observation matches observations from flash-induced spectroscopy: with a QB present in the 
wild-type protein, electron transfer has a lifetime of about 1 s, whereas, when QB is absent in the 
mutant, electron transfer has a lifetime of about 100 ms (Figure 4.8c). Previous studies that 
used a molecular additive to inhibit charge transfer from QA to QB observed a 10-fold reduction 
in lifetime of the charge-separated state, agreeing with this structural and spectroscopic 
observation.38 Through successfully optimizing the diffraction quality of crystals, this work 
demonstrates the application of microfluidic optimization chips as effective tools for streamlining 
crystallography and for supporting structure–function studies that require atomic-resolution 
crystal structures.  
Table 4.2: Crystallographic dataa and refinement statistics 
  
Unit cell dimensions (Å) a = b = 102.3     c = 240.3 
α = β = γ = 90° 
Space group P42212 
Resolution (Å) 47–3.49 
No. unique reflections 15,054 
Completenessb 88.3% (76.4%) 
Redundancyb 5.4 (5.4) 
Mosaicity (deg.) 0.13–0.27 
I/σb 5.5 (2.0) 
Rmergeb 0.290 (0.720) 
Number of frames 300 
Number of atoms  
Protein 6476 
Water 0 
Hetero 442 
Refinement  
R-work 0.251 
R-free 0.296 
Ramachandran statistics  
Most favored 96.0% 
Allowed 3.0% 
Disallowed 1.0% 
Average B-factors 
Protein 46.7 
Hetero 42.0 
  
a Merging of small data sets from 19 crystals analyzed on-
chip at room temperature 
b Values in parentheses indicate values for the highest 
resolution shells 
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4.6 Conclusions 
In summary, X-ray transparent microfluidic devices for in meso crystallization screening and 
optimization were developed that automated the formulation of mesophases for crystallization 
experiments in a high-throughput manner while consuming just a few nanoliters of membrane 
protein solution per condition. The high-throughput screening devices were validated by 
discovering crystallization hits for qNOR, cytochrome bo3 oxidase, and the LM-dimer of reaction 
center. The ability to survey 192 unique crystallization conditions in parallel with an X-ray 
transparent platform expedites extensive screening, crystal hit identification, and diffraction 
testing, all without opening or altering the device. In addition, the optimization devices were 
validated using the crystallization of the L223SW mutant of reaction center. Starting from a 
condition that yielded low quality crystals, fine-gradient re-screening of L223SW led to large, 
diffraction quality crystals. Data from these crystals were used to resolve a room-temperature 
structure with a 3.5 Å resolution. Compared to the wild-type reaction center structure, the 
L223SW structure verified that the S223W mutation inhibits the binding of a secondary 
ubiquinone to reaction center. For optimum performance of both devices, simple vacuum 
actuation and diffusive mixing are key to facilitating device-wide filling and incubation of all 
wells. The open-ended capillary valve enabled these devices to precisely measure as little as 8 
nL of protein solution to form a 13 nL crystallization-ready mesophase, a ~60% decrease in 
sample usage when compared to the most efficient in meso robots.39 While this technique is 
currently exclusive to laboratories with microfluidics expertise and their collaborators, the 
development of this technology into a commercially available product as an alternative to 
traditional in meso crystallization plates would provide immense advantages in user-friendliness 
and sample usage. 
The precise dispensing, control over fluid routing, and X-ray transparency in this type of 
microfluidic device may facilitate their use for other delicate, complicated, and labor-intensive in 
90 
meso crystallization experiments. As the field of crystallography pushes toward brighter X-ray 
beams and smaller crystals for serial crystallography,40–42 high-throughput devices that can grow 
hundreds of crystals on the same device (as reported here) provide an excellent fixed-target 
platform43–45 that has key advantages over continuous liquid-injection jets.46–49 Further, a more 
advanced device could facilitate crystal soaking, i.e., the on-chip introduction of heavy atoms or 
anomalous scatterers50–52 into the crystal post-crystallization for in situ, de novo phasing 
experiments. 
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CHAPTER 5 
Microfluidic Platforms for Crystallographic 
Studies of Protein-Ligand Interactions 
5.1 Introduction 
An area of significant interest in structural biology is the study of protein-ligand complexes, 
such as small drugs or biomolecules that bind or dock to the protein.1–3 Other important ligands 
include heavy atoms (metals) or other molecules to solve the crystallographic ‘phase problem’ 
for de novo structure solution through anomalous scattering or isomorphous replacement.4–8 
When planning a crystallization experiment, a key challenge is determining when and how to 
add ligand to the protein. Broadly, there are 4 methods of adding ligands to a crystallization 
experiment: (1) co-expression of protein with the ligand, (2) addition of ligands during 
purification, (3) co-crystallization of the protein with the ligand, or (4) soaking ligand into a grown 
crystal.9 Co-expression of protein with a ligand can increase levels of expression as well as 
increasing solubility. Ligand addition during purification is typically used when the expression 
system has been optimized, but the protein is still poorly behaved in solution. The remaining two 
methods, co-crystallization and soaking, can be tested during crystallization experiments. 
During co-crystallization experiments, ligand is added to the purified protein sample prior to 
crystallization, and is often used for ligands that are insoluble or aggregate easily. Soaking, the 
addition of ligand to grown crystals, is the most commonly used method because it does not 
require re-optimizing the expression, purification, or crystallization system and is typically easy 
to implement. 
Soaking experiments are typically prepared during the process of crystal harvesting, just 
prior to flash-freezing crystals for X-ray crystallography. Either the ligand solution is directly 
added to the mother liquor, or the crystal is removed from its mother liquor and equilibrated in a 
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separate ligand solution. The crystal then remains in the soaking solution for several hours to 
several days, depending on the protein-ligand system.9,10 Upon completion of the soak, the 
crystals are picked up with a crystallography loop and immediately plunged into liquid nitrogen 
as the final preparation step for X-ray crystallography. While straightforward for proteins 
crystallized in aqueous solution, extending this method to membrane proteins crystallized in 
meso adds several layers of complication.11 In meso crystallization is performed in hermetically 
sealed glass-sandwich plates, which are comprised of two thin layers of glass separated by an 
adhesive spacer.12 For soaking crystals in meso, the glass-sandwich plates must be carefully 
opened with a diamond-tipped scribe and forceps. Next, the soak solution is pipetted directly 
into the well, after which the glass is replaced and re-sealed with tape. After the soak (hours to 
days), the well is re-opened, the crystal harvested and then flash-frozen for X-ray 
crystallography. In a 2015 report from Caffrey and co-workers, the success rate for adding soak 
solutions was 5-10%, meaning that in 90-95% of all crystallization wells chosen for soaking, the 
crystal or crystallization well was compromised during the experiment (e.g., the glass-sandwich 
plate cracked, glass shards entered the well, crystals were lost, etc.).11 With the current state-of-
the-art in meso technology, ranging from specialized manual tools to robots, crystal soaking is 
prohibitively difficult.13–15 
In this work, we report a new microfluidic method for manipulation of crystals in meso after 
crystallization is complete and its application to the crystallization and soaking of a model 
protein-ligand system. In a 6-well X-ray transparent microfluidic array chip, crystallization and 
soaking were performed sequentially in a two-step process. First, crystals were first grown in a 
lipidic mesophases using the passive-mixing microfluidic method established in prior work 
(Chapter 2). Next, the mother liquor (remaining precipitant and depleted protein solution) was 
exchanged for a ligand-rich solution containing the inhibitor molecule using a new flow-through 
method. Protein crystals, which were embedded in the highly-viscous mesophase, remained 
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immobile while the mother liquor was displaced by the soak solution. The result was a facile and 
non-invasive method for solution exchange and ligand incorporation via soaking, where on-chip 
automation limited the possibilities for failure. The method was applied to the protein lysozyme 
and its inhibitor, triacetylchitotriose (tri-NAG),16 and validated through on-chip X-ray 
crystallography. The observed occupancy of tri-NAG in the crystal structures varied as expected 
with soaking time and tri-NAG concentration in the soak solution. 
5.2 Materials and methods 
For experiments described here, we used the following materials and chemicals: monoolein 
(1-Oleoyl-rac-glycerol) and cholesterol (Sigma–Aldrich, St. Louis, MO), polydimethylsiloxane 
(PDMS) (RTV-615 from Momentive Performance Adhesives, Waterford, NY), negative 
photoresists (SU-8 25 and SU-8 2050 from MicroChem Corporation, Newton, MA), cyclic olefin 
copolymer films (COC) (Grade 6013, 2 mil from TOPAS Advanced Polymers, Florence, KY), 
silanizing agent (tridecafluoro-1,1,2,2-tetrahydrooctyl)trichlorosilane from Gelest, Inc., 
Morrisville, PA), and epoxy (Conapoxy FR 1080 from Cytec Industries, Woodland Park, NJ). 
Sample preparation. To prepare the protein solution, powdered hen egg white lysozyme 
(Hampton Research, HR7-110) was used as received and dissolved in E-pure water (18.2 MΩ) 
at concentrations of either 50 mg/mL or 100 mg/mL. The precipitant solution was prepared with 
9% (w/v) sodium chloride in 0.1 M sodium acetate, pH 4.5 in E-pure water. The soaking stock 
solution was prepared at 16 µM tri-NAG (Toronto Research Chemicals, T735000) in E-pure 
water. Ligand-rich solutions for soaking experiments were prepared in a buffer with a similar 
composition to the mother liquor, 9% sodium chloride, 0.1 M sodium acetate, pH 4.5. 
Absorbance difference spectroscopy. Protein-ligand binding interactions in solution were 
verified by measuring the absorption spectra of lysozyme, and an equimolar mixture of 
lysozyme and tri-NAG. Measurements were performed with an Agilent 8453 UV-vis 
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spectrophotometer. Spectra for each sample were measured from 280nm – 320nm, and the 
resulting difference spectrum was analyzed.17  
Fabrication of soaking chips. Microfluidic chips were fabricated using a strategy adapted from 
previous work.18 For a full description, see Section 3.2. Briefly, patterned COC substrate layers 
were fabricated by hot embossing 50 µm thick sheets of COC with a high temperature epoxy 
master mold in a laminating press (Carver). Photoresist-on-silicon master molds were fabricated 
by photolithography using transparency photomasks (Figure 5.1). Compared to prior work, 
these photomasks have an extra feature which is key for flow-through soaking: an additional 
inlet hole located across from the protein inlet. Polydimethylsiloxane (PDMS), an elastomeric 
thermoset, was spin-coated on photoresist-on-silicon master molds to fabricate thin, patterned 
PDMS fluid and control layers by soft lithography. The chip layers were assembled through a 
Figure 5.1: Photomasks for the microfluidic platform for crystal soaking. The device contains three
patterned layers: (a) the control layer, (b) the fluid layer, and (d) the lipid compartment layer. The other
design for (c) the lipid filling chip, was used to fabricate an ancillary chip for deposit ~10 nL of lipid into
each lipid compartment. Photomasks were printed at 10,000 dpi on a Mylar transparency film (Fineline
Imaging). 
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combination of irreversible and reversible bonds. A blank COC layer was irreversibly bonded to 
the PDMS control layer by activating the surfaces with an atmospheric plasma treatment 
(Harrick) and then bringing them into direct contact. This COC–PDMS control layer was then 
irreversibly bonded to the PDMS fluid layer by a thermal bonding19 to form a COC–PDMS–
PDMS three-layer assembly (TLA). Prior to crystallization experiments, the compartments in the 
patterned COC substrate layer were filled with lipid (see Section 3.3.2). The crystallization wells 
in the TLA were aligned to the lipid compartments and reversibly bonded by surface adhesion to 
complete the construction of the chip. Vacuum interconnects were fabricated from PDMS blocks 
attached to PTFE tubing to facilitate vacuum actuation.  
Synchrotron X-ray data collection and analysis. X-ray diffraction data were collected at APS 
(Advanced Photon Source) synchrotron, Argonne National Laboratory at beamline 21-ID-F, LS-
CAT (Life Sciences Collaborative Access Team). In-line microscopes were used to center and 
focus on crystals with a 60 µm microbeam. The beamline operated at a fixed wavelength (λ = 
0.9795 Å). Data were collected in 1° steps with 1 s exposure and a sample-to-detector distance 
of 250 mm with a Rayonix MX-300 detector. Data from 10-15 crystals were collected for each of 
the 6 soaking conditions tested (Soaking time: 24 h, 48 h; Ligand-to-protein ratio: 1:1, 5:1, 10:1).  
All data were collected at room temperature, and an on-chip serial crystallography approach 
was utilized to mitigate the effect of radiation damage as demonstrated in prior work.18 
HKL2000 software was used for indexing, refinement, integration, and scaling multiple data 
sets together (HKL Research Inc.).20 Molecular replacement was performed with Phaser using 
PDB structure 5D5C as a model.18 Molecular replacement, structure building, and refinement 
were done using the Phenix suite of programs.21 Ligands bound to the structure were identified 
in the electron density and built into the final model. Electron density maps were displayed and 
compared using PyMOL. For each soaking condition, an optimal data subset was constructed 
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with diffraction from a minimum of 7 crystals for each of the 6 structures built. The maximum 
resolution of the structures ranged from 1.5 Å to 1.9 Å. 
5.3 Crystallization and soaking of a lysozyme-trisaccharide complex 
on-chip 
The goal of this work was to develop an on-chip, two-step process for (1) crystallization of 
proteins in a lipidic mesophase, and (2) subsequently soaking the newly grown crystals in a 
ligand-rich solution (Figure 5.2a). Similar to previous reports (Chapter 2), the soaking chip 
automates mesophase-based crystallization by passive mixing of protein, lipid, and precipitant. 
The second step, soaking of ligands, is enabled by a new fluidic path for flow-through filling 
through which the mother liquor can be displaced by the ligand-rich solution.  
For a crystallization-soaking experiment, first pre-deposited dry lipid was mixed with protein 
solution by diffusion across a large interface for several hours, which resulted in the formation of 
a stationary, protein-laden lipidic cubic phase. Crystallization was then triggered by the 
introduction of a precipitant solution – the precipitant compartment and protein-laden 
mesophase compartment meet in an open-interface ‘capillary valve’, which enabled complete 
mixing of precipitant into the mesophase.18,22 Crystals typically grow in the mesophase and 
reach their full size after a few days of incubation at 20°C. The mother liquor is then replaced 
with the ligand-rich solution. Ligands then diffuse through the mesophase and into crystal over 
several minutes to several days. Because the soaking chip is X-ray transparent, there is no 
need to harvest crystals for mounting – the entire microfluidic chip was mounted in an X-ray 
beam path for diffraction experiments to study protein-ligand interactions on a structural level. 
The soaking chip employs two different methods for filling solutions in sequence: first, dead-
end filling to formulate the crystallization trial, and then through-filling to replace the mother 
liquor with a ligand-rich solution (Figure 5.2b). To dead-end fill, vacuum is actuated adjacent to 
a microfluidic compartment to withdraw air, but not liquid, through a thin membrane. A solution 
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fills from a single inlet hole into the compartment in response to the displaced air, and the 
compartment will completely fill with liquid. Dead-end filling is the preferred method for 
accurately metering nanoliter volumes into a microfluidic chip because the size of the 
microfluidic compartment determines the amount of fluid filled. To through-fill, there must be a 
Figure 5.2: Schematics for in meso crystal soaking platform. (a) (left) An array of 6 parallel crystallization
wells for in meso crystallization and soaking. The fluid layer (black) contains channels and compartments
for all liquid solutions (inlets F1-F4). The control layer (pink) contains channels for vacuum actuation
(inlets C1-C3) – these features overlay fluid compartments and valves to automate filling and mixing.
(right) Inset of the top-down view for a single crystallization well showing the relative positions of the
control layer over the fluid layer. The protein and lipid chamber meets with the precipitant chamber across
a normally-open ‘S’-shaped capillary valve. Cross section X-X’ shows the layer-by-layer architecture of
the chip – from top to bottom, an impermeable COC (50 µm), the control layer (50µm), the fluid layer (50
µm), and an embossed substrate to hold lipid and additional precipitant (50 µm). (b) The platform
operates in two distinct modes: crystallization mode and soaking mode. (left) To operate in crystallization
mode, vacuum actuation at inlet C1 initiates protein filling through inlet F1. After a four-hour incubation,
vacuum actuation of inlet C2 fills precipitant solution from inlets F3 and F4. Inlets C3 and F2 are not used
in this mode. (right) To operate in soaking mode, vacuum actuation at inlets C1 and C3 opens the fluidic
path between F1 and F2. Withdrawal at inlet F1 will induce flow of a ligand-rich solution through the
crystallization chambers, from F2 to F1. 
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direct fluidic path between two inlet holes. For displacement of the mother liquor with a ligand-
rich solution, the ligand-rich solution is pipetted onto one inlet hole, and withdrawn through the 
other inlet hole (Figure 5.2c). Through-filling utilizes samples less efficiently, although it is the 
preferred method for rapid filling, or for when entire volumes need to be displaced. 
The use of dead-end filling is well-characterized for fluid filling and metering,23,24 and has 
been extensively tested for on-chip in meso crystallization.18,22 Three different methods of 
through-filling were evaluated for their compatibility with the mesophase and crystals in this 
study: (1) vacuum suction, (2) syringe pump withdrawal, and (3) wicking with an absorbent 
material. After the ligand-rich solution was deposited on the soaking inlet, the syringe pump 
withdrawal method was applied to the soaking outlet, resulting in flow from the inlet, through 
each of the 6 parallel crystallization chambers, and exiting through the outlet. Each method was 
tested experimentally with lysozyme crystals grown in lipidic mesophases with a dye solution in 
place of the ligand-rich solution to visualize the exchange of solutions (Table 5.1, Figure 5.3). 
With vacuum suction, the ligand-rich solution exchanged very rapidly (1 – 2 s) and crystals 
sustained significant damage (e.g., cracking, partial dissolution) during the exchange. Further, 
exchange by vacuum suction occurs very fast, meaning that a short extension of actuation time 
will fully evacuate the chip and ruin the crystallization experiment. Alternatively, syringe pump 
withdrawal resulted in slow (2 – 10 m), controlled solution exchange. These crystals sustained 
either no damage, or minor surface cracks which, later, did not impact X-ray diffraction 
experiments. Wicking with an absorbent material resulted in slow solution exchange (<15 min). 
Of the three, wicking is the most attractive method because no ancillary equipment is required 
Table 5.1: Summary of solution exchange methods 
Method Flow rate Time for exchange Crystal Behavior 
Vacuum suction >5 µL/s <2 s Cracks, dissolution 
Syringe pump 1 µL/min – 20 µL/min 2 – 10 min Minor cracks 
Wicking ~ 1 µL/min <15 min No change 
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for solution withdrawal, with primary drawbacks being that it is slow relative to the other 
methods and the flow rate is not controllable.  
The lysozyme/tri-NAG complex is a well understood protein-inhibitor system and an ideal 
model crystallization system due to the robustness of lysozyme crystals.16 Further, although 
lysozyme is a soluble protein, it crystallizes in the aqueous channels of lipidic cubic phases and 
is thus a suitable target for the initial application of soaking chips.25,26 Lysozyme natively 
Figure 5.3: Schematics (left) and optical micrographs (right) for operation of microfluidic platform in
soaking mode at various time points. (a) Schematic cross section of a microfluidic device after
crystallization – protein crystals are embedded in the mesophase. (b,e) 1 minute after ligand-rich solution
is placed at inlet F2, vacuum actuation is applied to inlets C1 and C3, and suction is applied with a
syringe pump in withdrawal mode at F1. Ligand-rich solution (red) begins to displace the mother liquor
(clear) in all 6 wells. (c,f) 5 minutes after initiation of flow, showing the soak solution further displacing the
mother liquor. (d,f) After ten minutes, flow-through reaches completion and the mother liquor is fully
replaced with ligand-rich solution. During an incubation step (several hours to days), the ligand diffuses
into the crystal. 
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functions as an antimicrobial protein by hydrolyzing 1,4-beta-linkages between certain 
saccharides in cell walls. Lysozyme’s active site has six locations where each saccharide can 
bond, and previous work has shown that tri-NAG: (a) is unhydrolyzable by lysozyme, and (b) 
binds preferentially in locations 2, 3 and 4 in the active site, and therefore acts as an inhibitor. 
Lysozyme/tri-NAG binding in solution was validated by absorbance difference spectroscopy. 
When mixed at a 1:1 molar ratio, the difference spectrograph showed the distinct ‘fingerprint’ of 
lysozyme/tri-NAG binding as demonstrated in literature.17  
Lysozyme crystallization was performed using the previously established on-chip in meso 
crystallization protocol. First, ~50 nL of 50 mg/mL lysozyme solution was filled in each 
mesophase chamber to passively mix with ~10 nL of solid monoolein. After a 24 hour pre-
incubation to allow for mesophase formation,27 ~ 240 nL of 9% (w/v) sodium chloride, 0.1 M 
sodium acetate, pH 4.5 was introduced to each crystallization well. Crystals were first observed 
after 12 hours and grew to their full size within 1-2 days. To evaluate the reliability of on-chip 
soaking of ligands into crystals in mesophases, two parameters were evaluated: (1) duration of 
soaking and (2) ligand-to-protein molar ratio. 6 different soaks were tested on-chip (in duplicate) 
Figure 5.4. 1.53 Å structure of the lysozyme/tri-NAG complex. (a) Ribbon diagram of 3-D structure, with 
secondary structure elements highlighted in red (α-helices) and yellow (β-strands). The tri-NAG molecule 
is shown as a stick representation at the binding site. (b) Surface rendering of the lysozyme/tri-NAG 
complex. (c) Electron density map of tri-NAG (yellow) in the binding site (blue), showing how tri-NAG 
aligns with residues on the surface of lysozyme. 2Fo - Fc density map is contoured to ±1σ. 
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with 24 or 48 hour soaks, and molar ratios of 1:1, 5:1, and 10:1. For all conditions, crystals did 
not sustain observable cracking or damage, and crystals were stable on-chip for at least 2 
weeks. Synchrotron X-ray diffraction experiments were performed after the conclusion of the 
soaks. For each condition, >10 crystals were analyzed using an established on-chip, room 
temperature method for serial crystallography.18,28,29 All crystals diffracted well (<2 Å), and the 
optimal data sets for each soaking condition were selected for structure solution (Figure 5.4).  
A structure was built for each of the 6 soaking conditions, and tri-NAG was bound to 
lysozyme at the lysozyme binding site in all structures. The structures had good overall quality 
with high resolution, high completeness, high I/sigma, and excellent R-factors (Table 5.2). 
There was minimal variation between the quality of crystal structures for bound and unbound 
lysozyme.26 While the tri-NAG was observed in all six soaking conditions, there were notable 
differences that depended on soaking time and ligand-to-protein ratio (Figure 5.5). At long soak 
Figure 5.5: Stick representations of tri-NAG from lysozyme structures at six different soaking conditions: 
(a) 24 hour soak and (b) 48 hour soaks at ligand-to-protein ratios of (i) 1:1, (ii) 5:1, and (iii) 10:1. The 
ligand is resolved in the structure best at high ligand-to-protein ratios, while lower occupancy or 
conformational flexibility is seen at lower ratios and soaking times. 
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durations and high ligand:protein ratios, the ligand electron density was easily recovered and 
the three rings of the tri-NAG were resolved in the crystal structure. At short soak durations and 
low ligand:protein ratios, only two of the three rings of tri-NAG were resolved in the crystal 
structure. This result was expected, and can be explained by two phenomena: first, the process 
of soaking is diffusion limited at low concentrations of tri-NAG as the ligand must diffuse into the 
crystal from the solution, resulting in a heterogeneous crystal with many proteins bound to tri-
NAG, and many proteins unbound. Thus, the final structure represents an average of both 
populations, resulting in a lowered tri-NAG occupancy. Second, the third ring of tri-NAG does 
not bind strongly to lysozyme and exists in many conformations when observed in the crystal 
structure, which results in structural disorder and reduced occupancy. 
Table 5.2: Crystallographic dataa and refinement statistics for lysozyme/tri-NAG complex 
Soak conditions: 1:1, 24h 5:1, 24h 10:1, 24h 1:1, 48h 5:1, 48h 10:1, 48h 
Unit cell (Å) a = b = 78.8 
c = 38.3 
α = β = γ = 90 
a = b = 78.9 
c = 38.2 
α = β = γ = 90
a = b = 79.0 
c = 38.2 
α = β = γ = 90
a = b = 78.8 
c = 38.3 
α = β = γ = 90
a = b = 78.8 
c = 38.2 
α = β = γ = 90 
a = b = 78.8 
c = 38.3 
α = β = γ = 90
Space group P 43212 P 43212 P 43212 P 43212 P 43212 P 43212 
Resolution (Å) 25.9 – 1.64 25.9 – 1.90 25.0 – 1.60 25.9 – 1.70 31.5 – 1.53 25.9 – 1.53 
No. unique reflections 15236 9338 15391 13763 18534 17549 
Completeness (%)b 98.8 (91.7) 94.22 (94.5) 93.4 (85.2) 99.3 (95.9) 98.8 (92.4) 93.4 (89.0) 
Redundancyb 13.3 (13.8) 7.6 (7.7) 8.7 (7.8) 14.3 (12.9) 6.8 (6.6) 8.0 (7.4) 
I/σb 28.5 (5.6) 23.7 (9.7) 20.5 (4.4) 31.1 (7.5) 20 (2.0) 26.5 (6.5) 
R-mergeb 0.111 (0.927) 0.160 (0.637) 0.156 (0.978) 0.209 (0.217) 0.159 0.090 (0.453)
Mosaicity (°) 0.05 – 0.73 0.04 – 0.87 0.07 – 0.41   0.03 – 0.39 
Number of atoms 1144 1134 1142 1176 1160 1151 
Protein 1000 1000 1000 1000 1000 1000 
Water 93 90 98 87 116 107 
Hetero 51 44 44 89 44 44 
Refinement       
R-workb 0.185 (0.199) 0.164 (0.178) 0.175 (0.190) 0.185 (0.175) 0.174 (0.210) 0.171 (0.201)
R-freeb 0.215 (0.232) 0.218 (0.232) 0.206 (0.263) 0.223 (0.235) 0.194 (0.250) 0.203 (0.253)
Ramachandran stats       
Most favored (%) 99 98 98 99 98 98 
Allowed (%) 1 2 2 1 2 2 
Disallowed (%) 0 0 0 0 0 0 
Average B-factors       
Protein (Å2) 14.7 18.2 16.0 13.7 17.6 15.5 
Hetero (Å2) 30.6 34.0 27.9 36.1 27.7 26.4 
a Merging of small data sets from multiple crystals for each structure, all analyzed on-chip at room temperature 
b Values in parentheses indicate values for the highest resolution shell  
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5.4 Conclusions 
In summary, an X-ray transparent device for in meso crystallization and ligand soaking was 
developed and applied to a protein and its molecular inhibitor. The device was designed to 
operate in two complementary modes: (1) crystallization via dead-end filling and (2) soaking via 
through-flow displacement. After crystals were grown on-chip as previously discussed (Chapter 
3), a ligand-rich solution was drawn from one end of the crystallization chambers to the other 
with the aid of suction to effectively displace the mother liquor with a new solution for the 
crystals to soak in. Three methods of suction were evaluated, and using a syringe pump in 
withdrawal mode and wicking with an absorbent material were the most effective for exchanging 
solutions without cracking crystals. The effectiveness of the soaking method and its sensitivity to 
ligand concentration and soaking time were evaluated through X-ray diffraction and structure 
building of a soaked lysozyme/tri-NAG complex. Notably, tri-NAG was observed in the structure 
at all soaking conditions, and increased occupancy was observed at higher ligand:protein ratios 
and soaking durations. Altogether, the microfluidic platform presented here provides a facile 
route to crystal growth and the incorporation of ligands in meso – compared to literature where 
many crystals are lost or damaged during the soaking process,11 crystals are never physically 
manipulated throughout the on-chip soak procedure. This feature preserves the quality of tens 
to hundreds of crystals as they are soaked simultaneously and then analyzed via in situ serial X-
ray crystallography.  
The on-chip crystal soaking procedure can be extended to study many proteins that 
crystallize in lipidic cubic phases and for other crystallographic techniques beyond ligand 
incorporation. For instance, to solve a membrane protein crystal structure de novo, 
crystallographic phasing data must be collected to solve the ‘phase problem’ through the 
soaking of heavy atoms or other anomalous scatterers into existing crystals. Alternatively, the 
growth of large crystals facilitates X-ray crystallography experiments, but membrane protein 
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crystals typically grow to small sizes. Pre-grown crystals can potentially be used as 
macroseeds, and the replenishment of membrane protein concentration in the mother liquor 
may result in the growth of larger crystals.  
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CHAPTER 6 
Summary and Future Directions 
6.1 Introduction 
Three-dimensional structures of membrane proteins reveal key insights into molecular 
function, although crystallization is a major bottleneck to structures. Microfluidic platforms can 
address these bottlenecks and provide many advantages in scalability and automation for 
membrane protein crystallization. Through my PhD work, I have expanded on these capabilities 
by developing X-ray transparent microfluidic platforms that facilitate powerful, yet cumbersome 
crystallization techniques. The work presented in previous chapters represents methods to 
facilitate multistep protein crystallization formulation for two primary techniques: (1) 
microseeded and (2) in meso crystallization. The thin construction (<200 µm) of these devices 
facilitates serial in situ X-ray crystallography, a key technique that prevents both physical 
damage and radiation damage from accumulating in crystals. Further, novel features such as 
microwell layouts and the development of an ‘always-open’ capillary microvalve enable multi-
step mixing and simplified handling of non-Newtonian lipidic phases.  
6.2  Microfluidic Platforms for Microseeding Protein Crystallization 
For most protein crystallographers, microseeding is typically used as a last resort 
optimization step due to the difficulty of implementation. The development of array chips is a 
noteworthy step toward routine usage for microseeded membrane protein crystallization. Using 
microfluidic array chips, microseeding was first demonstrated by pre-formulating a metastable 
protein-precipitant mixture for a model protein and its precipitant off-chip, and then filled into a 
microfluidic chip and mixed with dilutions of microscopic crystal nuclei solutions (microseed). 
This microfluidic technique provides a significant advantage for growing crystals for X-ray 
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diffraction because large crystals diffract better during X-ray crystallography. A second 
microfluidic device enabled microseed matrix screening (MMS) for screening many different 
compositions of crystallization solutions with microseeds. This devices separated mixing into a 
two-step process for on-chip formulation of metastable mixtures followed by addition of 
microseeds. In collaboration with the Gennis group, microseeding devices were applied to a 
membrane protein with a crystallization condition known to produce mediocre crystals, 
cytochrome bo3 oxidase. While not resulting in a high-resolution crystal structure after 
optimization, a thorough search of the protein-preciptant phase diagram with microseeds helped 
identify distinct composition regions where large crystals could be reliably grown. 
The studies here demonstrate the proof-of-principle for microseeding and MMS in 
microfluidic compartments applied to both soluble and membrane proteins. These devices can 
be further applied for (1) screening for and optimizing crystallization conditions for proteins of 
unknown structure, (2) surveying crystallization phase diagrams and solubility boundaries, and 
(3) implementing heterogeneous microseeds (non-protein, e.g. pulverized horse hair, cat 
whiskers, or seaweed) for proteins that do not produce crystalline results for microseed stocks. 
6.3  Microfluidic Platforms for In Meso Crystallization 
In meso crystallization remains the preferred technique for membrane protein crystallization 
because it typically produces high quality crystals. Despite the development and implementation 
of special tools and robots over the past 20 years, in meso crystallization remains a difficult 
technique to use for many crystallographers. Building from the efforts in the development of a 
microfluidic lipidic mixer by Perry et al.,1 the work detailed in Chapter 3-5 represent the 
development and applications of the first microfluidic X-ray transparent devices for in meso 
crystallization. By relying on passive mixing,2,3 where membrane protein solution mixes into the 
lipid by diffusion, rather than active mixing,1 on-chip formulation became a much simpler and 
repeatable process. After the development and application of the chip for proof-of-principle 
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studies,3 the work was expanded into routine crystallization tasks of (1) high-through screening 
and optimization,4 and (2) in situ crystal soaking. Notably, the work here meets or exceeds the 
sample usage (<10 nL of protein per well) and level of automation (high-throughput formulation, 
soaking) in state-of-the-art in meso crystallization techniques. Through these applications, three 
protein structures were solved: room temperature structures of a reaction center, a mutant of a 
reaction center, and a lysozyme/inhibitor complex. Several crystallization hits were identified for 
proteins of unknown structure, although none yielded a crystal structure.  
There are a few future directions for in meso microfluidic devices. The development of these 
in meso microfluidic devices is mature enough where they can be implemented for routine use 
in research labs on a small-scale. The Kenis group has shared devices and documentation with 
a few research labs in the crystallographic community for crystallization screening and 
optimization for membrane proteins of unknown structure, as well as for soaking of membrane 
protein crystals, and these works are ongoing. There are opportunities to extend the capabilities 
of in meso soaking devices to new applications, such as de novo phasing and in meso seeding. 
De novo phasing techniques, such as isomorphous replacement or anomalous dispersion, are 
also difficult tasks for in meso crystallization because they require post-crystallization 
incorporation of heavy atoms or other scatterers. A method for in meso seeding is also 
appealing because membrane protein crystals are often small or too small for crystallization. 
Recently, a benchtop approach has been demonstrated where small crystals are pre-grown in a 
mesophase, which is then used for a crystallization trial.5 With the soaking chip, a two-step 
seeding process can be developed where small crystals are first grown on-chip, then those 
crystals act as seeds for larger crystals when the protein concentration is replenished by 
solution replacement. 
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6.4 Concluding Remarks 
Despite the noted advantages to using microfluidics for microseeding and in meso 
crystallization, most laboratories do not have the capabilities of producing devices for their own 
experiments. A commercial route to crystallization chip production would be ideal, although 
most companies in the microfluidic sector refrain from using PDMS due to issues with scale-up 
and manufacturability.6 The industry standard materials, such as polymethylmethacrylate or 
polycarbonate, do not exhibit the same elastomeric behavior as PDMS which is necessary for 
the implementation of normally open or normally closed valves. Either new manufacturing 
methods need to be explored or developed for producing multilayer PDMS elastomer devices, 
or thermoplastic elastomers (e.g., SEBS7) that are more amenable for processing must be 
substituted for PDMS.  
In summary, the work presented here represents a significant step forward in the 
implementation of microseeded and in meso crystallization coupled with in situ crystallography. 
These microfluidic approaches address key experimental requirements of low sample 
consumption, high-throughput automation, and in situ analysis. There are several future 
directions for these projects, and the solution of a membrane protein target of unknown 
structure would demonstrate the full potential for microfluidic crystallization devices. A wide-
scale implementation of the devices detailed in this dissertation, which would get these 
technologies into the hands of expert protein crystallographers, could accelerate the membrane 
protein structural pipeline and help alleviate the crystallographic bottleneck. 
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